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Abstract 
Posttraumatic stress disorder (PTSD) is a psychiatric condition that presents with 3 main 
symptoms—re-experiencing, avoidance/numbing, and hyper arousal—after an individual 
experiences a traumatic event. Recent evidence suggests a potential genetic basis for 
PTSD and a sub symptom of hyper arousal, sleep, as a potential pathway for PTSD 
development, but no study has identified candidate genes associated with specific 
symptoms such as sleep difficulty. Based on a conceptual framework in which specific 
genes are associated with the onset of PTSD, this study used a genome-wide association 
study (GWAS) method with a case control study design to compare the genomes of 
individuals with and without PTSD. A secondary GWAS dataset from a study on alcohol 
dependence in European and African Americans was obtained from the National Center 
for Biotechnology Information. PTSD cases and controls were analyzed using PLINK 
software. Signals from 2 single nucleotide polymorphisms (SNPs), which have not been 
previously associated with PTSD, exceeded the established genome-wide threshold: SNP 
rs13160949 on chromosome 5 (p = 7.33x10
-9
, OR: 1.565) and SNP rs2283877 on 
chromosome 22 (p = 2.55x10
-8
, OR: 1.748). Neither SNP, though, maintained genome-
wide significance following corrected tests for multiple testing, population stratification, 
and false discovery, so the planned analysis for possible associations with PTSD by 
symptom category then by the sub symptom of sleep could not be completed.  The results 
of this study suggest that PTSD may be the result of polygenic SNPs with weak effects, 
which supports a recent study indicating the disease may be highly polygenic.  Positive 
social change implications include bringing attention to the clinical and research 
community that PTSD may involve complex polygenic factors in need of further study.  
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Chapter 1: Introduction to the Study 
Posttraumatic stress disorder (PTSD) is a psychiatric condition that develops in  
some individuals following a traumatic event.  Prevalence rates indicate that only a 
portion of individuals (3.6%) develop PTSD during a 12-month period despite a majority 
of individuals (80%) experiencing a traumatic event (Frans, Rimmo, Aberg, & 
Fredrikson, 2005; National Comorbidity Survey, 2007; Yehuda, Koenen, Galea, & Flory, 
2011).  Some individuals may be more susceptible due to psychological factors, which 
may be influenced by the genetic makeup of the individual.  Feodorova and Sarafian 
(2012) and Koenen (2007) have suggested that genetic risk factors should be considered 
when variance is greater than 30%.  A 37-41% variance has been found in PTSD 
heritability studies (Bailey et al., 2010; Goenjian et al., 2012).   
Human genome epidemiology (HuGE) is a field of epidemiology that uses 
epidemiological approaches to study variations in disease associated with genetics 
(Khoury, Little, & Burke, 2004).  In this dissertation, I proposed a human genome 
epidemiology approach to discover possible genetic risk factors associated with 
posttraumatic stress disorder.  Using a case control study design and a genome-wide 
association study method (GWAS), the genome of individuals with PTSD was compared 
to that of controls.  A database containing genomic data for individuals with PTSD was 
requested from the National Center for Biotechnology Information (NCBI).  The database 
that contained the PTSD dataset was from an original study, phs000425.v1.p1, “Alcohol 
Dependence GWAS in European and African Americans” (Gelertner & Kranzler, 2010).  
In this dissertation I focused on the sub symptom of sleep that is part of the hyper arousal 
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symptom of PTSD.  Initial analysis consisted of a multistep process that examined the 
entire genome (PTSD cases vs. controls).  Any gene/genetic allele that reached 
significance was further analyzed to determine whether an association existed between 
the genetic allele and the main symptoms of PTSD, re-experiencing/intrusion, 
avoidance/number, and hyper arousal, including the sub symptom of sleep.  A study by 
Bailey et al. (2010) examined heritability of PTSD and the symptoms associated with 
PTSD and found support for both the heritability of PTSD (0.37) and the symptoms of 
PTSD (re-experiencing 0.75, avoidance and hyper arousal 0.39.  As mentioned, sleep is 
part of the hyper arousal symptoms.  There have been four GWAS published on PTSD; 
however, none of these studies examined the symptoms of PTSD, and none focused 
specifically on the symptom of sleep (Guffanti et al., 2013; Logue et al., 2012; Solovieff 
et al., 2014; Xie et al., 2013).   
Recommendations from the literature support further study of the link between 
PTSD and sleep as a potential pathway for PTSD development (Krakow, Germain, et al., 
2001; Krakow, Hollifield, et al., 2001; Walker & van der Helm, 2009; Yetkin, Aydin, & 
Ozgen, 2010).  Sleep difficulties in the form of insomnia, poor sleep quality, and 
nightmares are reported by 70-91% of individuals diagnosed with PTSD (American 
Psychiatric Association [APA], 2000; Maher, Rego, & Asnis, 2006). Studies that focused 
on treating sleep problems have resulted in improvements in sleep functioning, symptoms 
of posttraumatic stress disorder, and cognitive functioning, particularly long-term verbal 
memory (Krakow, Hollifield, et al., 2001; Raboni, Suschecki, & Tufik, 2009; Ulmer, 
Edinger, & Calhoun, 2011).  Walker and van der Helm’s (2009) “sleep to remember 
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sleep to forget” hypothesis suggests that sleep is not a symptom of PTSD but rather a 
causal factor for its development.  Stickgold (2002) has suggested that PTSD develops as 
a function of neurotransmitter failure or disruption preventing normal integration of 
memory processes.  This memory processing occurs during sleep; “posttraumatic re-
enactments in the form of nightmares or dreaming are understood as a psychological 
correlate of pathological changes to normal brain functioning during rapid eye movement 
(REM) sleep” (Wittman, 2007, p. 4).   
One of the completed GWAS lends support for further study of PTSD and sleep 
difficulty (Logue et al., 2012).  Logue et al. (2012) found SNP rs8042149 in the retinoid-
related orphan receptor alpha gene (RORα) associated with PTSD.  The RORα gene is 
thought to be involved in circadian rhythm functioning and in the circadian clock (Akashi 
& Takumi, 2005).  Additionally, there is one candidate gene, catechol-o-
methyltransferase (COMT), that has been studied in both PTSD and sleep research (Goel, 
Banks, Lin, Mignot, & Dinges, 2001; Kolassa, Kolassa, Ertl, Papassotiropoulos, & 
DeQuervain, 2010).     
Positive social change implications of this research include bringing attention to 
the  genetic risk factors associated with PTSD, a disorder for which there has been little 
attention devoted to genetic risk factors compared to other disorders such as major 
depression or schizophrenia and highlighting methodological concerns related to the 
GWAS method (Cornelius, Nugent, Amstadter, & Koenen., 2010).  Prior to background 
information on PTSD being provided, some basic concepts surrounding genetics and 
genomic research are reviewed to provide understanding of the dissertation.  Genomics is 
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the study of individual gene functioning as well as genetic functioning in the context of 
the larger genome (Guttmacher, 2002, as cited by Khoury et al., 2004).  Peyser and Burns 
(2004) suggested, 
Different genetic backgrounds may cause genetic susceptibility to the same 
disease.  Genes that confer a high risk may be present in only a subset of affected 
persons.  The trait may be caused by different genetic loci acting together, or a 
predisposing gene may only manifest in the presence of a particular 
environmental exposure. (p. 39) 
Other terms used in genetics are genotype and phenotype.  Genotype is the 
nonobservable information contained in a gene and has to be identified through genetic 
tests; this is the genetic makeup of an individual that is contained in alleles (“Examples of 
Genotype & Phenotype,” 2013).  Alleles are “pairs or series of genes on a chromosome 
that determines the heredity characteristic…an example of an allele is a gene that 
determines eye color” (“Allele,” 2013, ¶1).  Phenotype is the notable difference that can 
be identified from the interaction between the environment and the gene (Peyser & 
Burns, 2004).  Examples of phenotypes are observable differences that can be seen in hair 
and eye color (“Examples,” 2013).  In the literature and in this dissertation, the term 
candidate gene studies refer to individual genes or genotype, though specific references 
may be made to phenotype.  Another relevant term is single nucleotide polymorphisms 
(SNPs), which are variations that occur at one nucleotide; for example, an A may be 
replaced with a C in a genetic sequence (Ellsworth & O’Donnell, 2004).  These basic 
concepts should assist the reader in understanding this dissertation.   
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Background Information 
Posttraumatic stress develops in some individuals following an experience in 
which their life was in danger or they witnessed a traumatic event that left them feeling 
an “intense fear, helplessness, and horror” (APA, 2000; Frans, et al., 2005; Pietzral, 
Goldstein, Southwick, & Grant, 2011; U.S. Department of Veterans Affairs: National 
Center for PTSD, 2007).  The symptoms associated with PTSD are re-
experiencing/intrusion, avoidance/numbing, and hyper arousal, with sleep difficulty 
being part of the hyper arousal symptoms.  Diagnostic criteria for each of these 
symptoms are provided in the Appendix (APA, 2000).  
The literature on PTSD is extensive and has focused on trauma exposure, gene 
candidate studies, gene expression studies, biological mechanisms, environmental and 
social risk factors, and, most recently, GWA studies (Guffanti et al., 2013; Logue et al., 
2012; Koenen, Amstadter, & Nugent, 2009; Kolassa, Kolassa, et al., 2010; Morey et al., 
2011; Schmidt, Holsboer, & Rein, 2011; Solovieff et al., 2014; Uddin et al., 2011; Xie et 
al., 2013; Yehuda et al., 2011).  These studies have primarily focused on the disorder of 
PTSD, with very few candidate gene studies focusing on the individual symptoms 
associated with PTSD; no GWAS have studied PTSD symptoms, and none have focused 
on the role sleep may play in the development of PTSD.   
Candidate genes associated with PTSD have included the following: “G” alleles 
of rs12944712 of the corticotrophin-releasing hormone (CRH) receptor 1 gene, the solute 
carrier family 6 (neurotransmitter transporter) member 3 (SLC6A3) dopamine active 
transporter 1 (DAT1) allele; the SLC5A3 locus (DAT1 or DAT) 9R allele, the dopamine 
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receptor D2 (DRD2) region of the dopamine system with the 957 C>T polymorphism 
specific to the “C” allele, the variable number tandem repeat (VNTR) polymorphism on 
exon III of the DRD4 gene, long DRD4 variants (seven-repeat ones), and the 
dystrobrevin binding protein (DTNBP1) SNP rs9370822 allele (Amstadter et al., 2011; 
Change et al., 2012; Dragon & Onisczenko, 2009; Segman et al., 2002; Voisey et al., 
2010; Voisey et al., 2009).  Other genes associated with PTSD were the FK506 binding 
protein (FKBP5), the glucocorticoid receptor, the serotonin transporter linked gene 
polymorphic region (5HTTLPR, the “L” allele, rs16965628 with a “GG” genotype, allele 
frequency “s/s” carriers at region 7q11-1-q12) and in Intron 2 (VNTR), the 12 allele 
(Hauer et al., 2011; Lee et al., 2005; Morey et al., 2011; Sarapas et al., 2011; Sayin et al., 
2010).  Ressler et al. (2011) found SNP rs2267735 part of the adenylate cyclase 
activating polypeptide 1 (pituitary) receptor 1 (ADCYAP1R1) predicted PTSD in females 
only.  Lee et al. (2011) found that the “CC” genotype of rs2267735 in women was 
associated with total PTSD symptoms and hyper arousal symptoms.  A study related to 
variance found the “t” allele of tryptophan hydroxylase 1 (TPH1), SNP rs2108977 
accounted for 3% of the variance while the “s” allele of the TPH2, SNP rs11178997 
accounted for 4% of the variance in PTSD (Goenjian et al., 2012).   
While these studies have advanced the understanding of potential genetic risk 
factors, other studies have found no association or mixed results (Bailey et al., 2010; 
Mellman et al., 2009; Morgan et al., 2003; Pivac, Kozaric-Kovacic, & Muck-Seler, 2006; 
Sah et al., 2009).  No associations were found between allele, genotype, or frequency for 
the brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism or plasma 
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dopamine betahydroxylase (DBH) and 5-HT (Lee et al., 2006; Pivac et al., 2006).  
Mellman et al. (2009) found no association with the 5HTTLPR, functional genotypes 
high expression (HE) or low expression (LE).  Two genes associated with the 
dopaminergic systems DRD2 and DAT were also not associated with PTSD (Bailey et 
al., 2010; Pivac et al., 2006). 
Mixed results have been found in the gene associated with resiliency that may 
confer a protective factor, Neuropeptide Y.  Morgan et al. (2003) found a negative 
association between Neuropeptide Y receptors (NYP), the number of traumatic life-
threatening events, and PTSD symptoms, suggesting that exposure to trauma rather than 
PTSD symptoms was related to lower NPY levels; Sah et al. (2009) found that PTSD 
cases had lower levels of NPY compared to healthy controls and suggested that higher 
levels of CSF NPY may serve as a protective factor in some individuals.  Limitations 
noted in candidate gene studies have included small sample sizes, methodology 
problems, trauma exposure and severity, co-occurring disorders associated with PTSD, 
and the disorder itself in terms of its complexity (Cornelius et al., 2010; Norrholm & 
Ressler, 2009).  Koenen (2007) indicated that identifying which specific genes to study 
presents challenges to researchers, as associations may be missed due to incorrectly 
studying irrelevant genes. 
There were no published GWA studies of PTSD prior to 2012; recommendations 
from the literature on PTSD indicated that a genome-wide association study was needed 
to fill this gap in the literature (Cornelius et al., 2010; Feodorova & Sarafian, 2012; 
Norrholm & Ressler, 2009).  Since 2012, four genome-wide association studies have 
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been published examining PTSD, each finding novel genes (SNPs rs363276 in 
SLC18A2, RORα, Tolliod-Like 1 gene [TLL1], SNP rs10170218 in ACO68718.1) not 
previously identified in the literature (Guffanti et al., 2013; Logue et al., 2012; Solovieff 
et al., 2014; Xie et al., 2013).   
Problem Statement 
While the recent GWAS have found new genetic alleles, none of the studies 
examined the potential relationship between genetic alleles and the symptom of sleep.  
The GWAS study by Logue et al. (2012) lends support for further study of PTSD and 
sleep.  The RORα gene identified by Logue et al. is a gene thought to be involved in 
circadian rhythm functioning and in the circadian clock (Akashi & Takumi, 2005).  This 
finding is intriguing, as sleep disturbance is noted as a symptom associated with PTSD in 
the form of insomnia, poor sleep quality, and nightmares.  The literature suggests an 
intimate relationship between sleep and PTSD, with sleep problems identified as a “core 
feature” of PTSD (Germain, Buysse, Shear, Fayyad, & Austin, 2004; Krakow, German, 
et al., 2001; Krakow, Hollifield, et al., 2001; Yetkin et al., 2010, p. 309).   
Boscarino, Kirschner, Hoffman, and Ehrlich (2013) found that the best predictors 
of PTSD were a high lifetime trauma exposure, a history of major depression, and a 
history of reported sleep problems (p < 0.001).  Recommendations from the literature 
also support further study of this link between PTSD and sleep as a potential pathway for 
PTSD development (Krakow, Germain, et al., 2001; Krakow, Hollifield, et al., 2001; 
Walker & van der Helm, 2009; Yetkin et al., 2010).  Studies that have focused on treating 
sleep problems have resulted in improvements in sleep functioning, symptoms of 
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posttraumatic stress disorder, and cognitive functioning, particularly long-term verbal 
memory (Krakow, Germain, et al.,  2001; Krakow, Hollifield, et al., 2001; Raboni et al.,  
2009; Ulmer et al., 2011).  Walker and van der Helm’s (2009) “sleep to remember sleep 
to forget” hypothesis suggests that sleep is a causal factor for the development of PTSD.  
Sleep dysfunction is viewed as a primary determinant for PTSD development and was the 
theoretical framework used for this research, with an explanation provided in the 
theoretical framework section (Walker & van der Helm, 2009).   
Purpose of the Study 
This purpose of this dissertation study was to examine the genomes of individuals 
with PTSD and controls to discover whether there are genomic regions associated with 
PTSD, specifically concerning the symptom of sleep.  The independent variable was 
PTSD status (i.e., PTSD case population vs. non-PTSD control population).  The 
dependent variables were the symptoms associated with PTSD (re-
experiencing/intrusion, avoidance/numbing, hyper arousal, and specifically the sub 
symptom of sleep).  The analysis examined the genome of individuals with and without 
PTSD with a second analysis planned with the main symptoms of PTSD and the variable 
of sleep for any alleles that exceeded the genome wide association threshold.  
Confounding variables identified in the literature included the following: BMI, age, 
gender, race/ethnicity, use of anxiolytics, antidepressants, socioeconomic status, type and 
intensity of trauma, education, rural/urban, co-occurring disorders such as major 
depressive disorder, drug dependence, substance abuse, Axis 2 disorders, and age of 
traumatic exposure (Babson et al., 2011; Frans et al., 2005; Krakow, Germain, et al., 
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2001; Krakow, Hollifield, et al., 2001).  Confounding variables that were included were 
the variables included in the database (i.e., age, gender, race, stimulant dependence, 
sedative dependence, tobacco dependence, and substance abuse).   
Research Questions 
The genome-wide method is not a hypothesis-driven method but rather a 
discovery-driven method.  This method is similar to casting a wide fishing net and seeing 
what is found.  Therefore, specific hypotheses are not provided; however, the following 
research questions were considered: 
 Research Question 1: Are there significant genetic alleles associated with 
PTSD? 
 Research Question 2: Is there a significant association between genetic 
allele(s) and the symptoms of PTSD? 
 Research Question 3: Is there a significant association between genetic 
allele(s) and the symptom of sleep? Is either the COMT or RORα, both 
genes that have been identified in sleep and PTSD, associated with sleep? 
Walker & van der Helm Theoretical Foundation 
The foundation of this dissertation was a novel conceptual framework by Walker 
and van der Helm (2009) “sleep to remember sleep to forget” because of its focus on 
sleep as the mechanism for PTSD development.  Walker and van der Helm suggested that 
sleep dysfunction is not just a symptom associated with PTSD, but may be a possible 
pathway for the development of PTSD.  They suggested that PTSD develops as a result 
of a failure in processing emotionally laden content due to impaired sleep (Walker & van 
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der Helm, 2009).  Lee and Douglass (2010) indicated that although the “function of sleep 
is unknown, decades of research strongly implicates that sleep has a vital role in the 
central nervous system (CNS) restoration, memory consolidation, and affect regulation” 
(p. 403).  Walker (2009) indicated that sleep is involved in different processes related to 
memory, cognition, brain plasticity, and psychiatric disorders.  Brain plasticity refers to 
changes that occur in the brain’s structure and function based on exposure to new, 
different, or complex experiences (Kolb & Gibb, 2011; Kolb, Gibb, & Robinson, 2003).  
Brain plasticity occurs throughout one’s lifetime and can be impacted by epigenetics, 
hormones, stress, experience, drugs, anti-inflammatory medications, diet, disease, and 
brain injury (Kolb & Gibb, 2011; Kolb et al., 2003).  Dang-Vu, Desseilles, Peigneux, and 
Maquet (2006) suggested that sleep plays a role in brain plasticity by impacting learning 
and memory.   
Walker (2009) suggested that sleep, particularly REM sleep, may impact the 
emotional response of memory.  Walker (2009) indicated that sleep is important to both 
encode and form lasting memories.  Declarative memory is a type of memory involved in 
the recall of facts and concepts (Martin, 1993).  This type of memory is thought to be 
affected by stressful events, with sleep enhancing declarative memory processing (Golier, 
Harvey, Legge, & Yehuda, 2006; Walker, 2009).  Memories are thought to be accessed 
during the sleep cycle (Walker, 2009).  Walker indicated that declarative memory 
consolidation may occur during short-wave sleep and takes place in the hippocampus 
region of the brain.  Walker suggested that sleep deprivation may impact one’s memory 
by magnifying negative emotional content while decreasing positive emotional content 
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(Zohar, Tzischinsky, Epstein, & Lavie, 2005, as cited by Walker, 2009).  For a more 
detailed discussion of the “sleep to forget and sleep to remember” framework, see 
Chapter 2 (Walker & van der Helm, 2009, p. 741).   
Conceptual Framework 
There have been no studies to date that have focused on sleep difficulties and 
PTSD in the context of potential genetic vulnerabilities; however, COMT and SNP 
rs8042149 in the RORα gene have been associated with PTSD (Kolassa, Ertl, et al., 
2010; Kolassa, Kolassa, et al., 2010; Landolt, 2008; Logue et al., 2012).  The RORα gene 
is thought to be a gene involved in circadian rhythm functioning (Akashi & Takumi, 
2005).  The RORα gene was found to be important in regulating Bmal1 transcription 
factor in mice (Akashi & Takumi, 2005).  When the RORα did not function properly in 
promoting Bmal1, the circadian rhythm did not function properly; the RORα is 
considered a “component of the core circadian clock”… and “acts as to promote Bmal1 
transcription, thereby maintaining a robust circadian rhythm” (Akashi & Takumi, 2005, 
p. 441).  The RORα gene may be involved in chronic inflammatory processes such as 
heart disease or arthritis (Delerive et al., 2001); Boscarino (2008) found that individuals 
with higher PTSD scores had a 20% increased risk of mortality from heart disease.   
The literature suggests an intimate relationship between sleep and PTSD; sleep-
disordered breathing (SDB) or sleep movement disorders (SMD) have been reported in 
77% of sexual assault survivors (Krakow, Hollifield, et al., 2001).  Kobayashi, Boarts, 
and Delahanty (2007) indicated that a frequent complaint of individuals diagnosed with 
PTSD is sleep disturbances.  Kobayashi et al. found that individuals diagnosed with 
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PTSD compared to individuals without PTSD spent more time in Stage 1 sleep, had less 
slow-wave sleep, and exhibited an increase in REM density.  Other sleep difficulties have 
included difficulty with sleep onset, sleep maintenance, and nightmares, which have been 
significantly related to severity of PTSD symptoms (Babson et al., 2011).  Germain et al.  
(2004) examined subjects with PTSD who also had untreated sleep disturbances and 
found that as sleep problems increased, overall PTSD symptoms increased as well.  
Increased sleep disturbances were unrelated to gender, age, type of trauma, length of 
PTSD, or other co-occurring psychiatric conditions (Germain et al., 2004).  Krakow, 
Germain, et al. (2001) found that sleep quality and PTSD both predicted sleep disordered 
breathing (SDB) and sleep movement disorders (SMD); further analysis after controlling 
for other factors indicated that only PTSD predicted SDB or SMD and SDB combined.  
They recommend further consideration of a potential relationship between sleep quality, 
sleep disorders, and PTSD (Krakow, Germain, et al., 2001).  Genetic risk factors have 
been identified for sleep disorders including restless leg syndrome, insomnias, and 
obstructive sleep apnea syndrome (Dauvilliers & Tafti, 2008).  Tafti (2009) 
recommended a GWAS to examine normal sleep and sleep disorders. 
Deductive and inductive reasoning was used to develop this research idea.  
According to deductive reasoning, if sleep is a primary risk factor for the development of 
PTSD and genes are associated with both PTSD and sleep, then studying the genome 
may result in identifying a common genetic risk factor for sleep and PTSD.  According to 
inductive reasoning, treating nightmares decreases nightmare frequency and/or improved 
sleep and PTSD symptoms, suggesting that treatment for sleep problems results in 
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improvement in PTSD (Krakow, Germain, et al., 2001; Krakow, Hollifield, et al., 2001).  
Refer to Chapter 2 for a more detailed discussion of the literature review.  Figure 1 
provides a flow chart for the reader to conceptualize the variables in this study.   
GWAS analysis using PLINK software to discover genetic alleles associated with PTSD
Genetic allele(s) reaching 
significance go to second analysis 
(t-test, chi-square, OR)
SSADDA Tool
Variable: Re-
experiencing
Variable: 
Avoidance
Variable: 
Hyper 
arousal
PTSD Cases
PTSD
Variable:
Sleep
Controls
Variables 
Controlled 
for include: 
Age, Gender, 
Race, and 
Substance 
Abuse
 
Figure 1. Conceptual flowchart of PTSD variables.   
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Nature of the Study 
The GWA approach has been considered “a completely untapped avenue for 
future research in measured genes and PTSD” (Cornelius et al., 2010, p. 8). The National 
Center for Biotechnology Information’s (NCBI) had a de-identified PTSD dataset 
collected as part of another GWAS study.  I applied to use the genome-wide association 
database which was available through the Database of Genotypes and Phenotypes 
(dbGAP) website (Gelertner & Krazler, 2010).  The original study collected genomic data 
on the symptoms of PTSD and was completed as part of a larger dataset on alcohol 
dependence in European and African Americans. Quantitative data consisted of genomic 
data on PTSD from this database.  Molecular data were collected using whole-genome 
typing with the Illumina chip HumanOmni1_Quad_v1-0_B (dbGAP, n.d.).  The variables 
collected from the dbGaP included the following: gender, age, race, sedative dependence, 
tobacco dependence, stimulant dependence, and substance use (Gelertner & Krazler, 
2010).    The dbGaP database used de-identified data from the National Library of 
Medicine’s National Center for Biotechnology Information (NCBI).  NCBI indicates that 
in some instances, dbGAP provides individual-level participant data for the purpose of 
follow up.  A request was made to access individual-level data for the purpose of 
completing the study.   
The use of this database requires a doctoral level individual to be the principal 
investigator (PI) along with the signing official (SO) to be able to access the database.  
The signing official for my use of this database was required to be someone from Walden 
University, either the head of the department or a designee from Walden.  Dr. Shen 
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agreed to be the PI for the purpose of obtaining the database; however, I completed the 
research project.  Both the PI and the SO cosigned the data access request.  The data 
access request form, SF424 (R&R) required both the PI and SO to have accounts through 
the National Institutes of Health (NIH) and eRA Commons.   
Spencer, Zhan, Donnelly, and Marchini (2009) reviewed design issues related to 
genome-wide association studies.  They suggested that a GWA research design has to 
account for the type of chip used to complete the study and an adequate sample size to 
detect an effect.  They reviewed several different types of chips that can be used and 
suggested that the number of cases to controls be between 1,257 and 2,653 to obtain 
power from 0.635 to 0.821 (Spencer et al., 2009).  The Illu610 k chip requires 2,212 
cases and 2,212 controls to obtain a power of 0.818, “assuming a disease causing allele 
with a relative risk of 1.5, a minor allele of at least 0.05, and a p value threshold of p < 
5x10
-7” (Spencer et al., 2009, p. 9).  Zondervan and Cardon (2007) suggested that a 
sample size of 1,000 cases and controls is needed to detect an odds ratio of ~ 1.5 with 
80% power.  Three of the four genome-wide association studies have had smaller sample 
sizes: Logue et al. (2012, 295 cases of PTSD), Xie et al. (2013, 300 cases of PTSD), and 
Guffanti et al. (2013; 94 cases of PTSD).  The fourth study by Solovieff et al. (2014) had 
a larger number of PTSD cases (n = 845).  Prior to obtaining the database the website 
information indicated the database contained 500 PTSD cases and 491 controls.  The 
entire sample from the NCBI database was used.  The independent variable was PTSD 
status (PTSD case population vs. non-PTSD control population).  The dependent 
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variables were the symptoms of PTSD: re-experiencing/intrusion, avoidance/numbing, 
hyper arousal, and sleep); refer to Chapter 3 for additional information. 
Confounding variables included those variables included as part of the database: 
age, gender, race/ethnicity, sedative dependence, tobacco dependence, stimulant 
dependence, and substance use.  I acknowledge that other variables in the literature were 
not included in this study, including BMI, use of anxiolytics, use of antidepressants, 
socioeconomic status, type and intensity of trauma, education, rural/urban, co-occurring 
disorders such as major depressive disorder, Axis 2 disorders, and age of traumatic 
exposure, and this is noted in the limitations of the study (Babson et al., 2011; Frans et 
al., 2005; Krakow, Germain, et al., 2001; Krakow, Hollifield, et al., 2001).     
Demographics for participants were included.  The genomic data were analyzed 
initially using PLINK software to identify any area of the genome that reached genome-
wide significance.  Statistical measures included frequency, means, and odds ratio of 
genetic alleles for PTSD cases and controls.  Groups were analyzed to ensure that they 
did not differ using Hardy-Weinberg equilibrium.  Any gene that reached genome-wide 
significance moved to the second phase of analysis to be further analyzed with the 
dependent variables.  This was done using SPSS and included comparison of t test and 
chi square.  Odds ratio was calculated, as appropriate.     
Definitions 
The db GAP database identified individuals with PTSD using the Semi-Structured 
Assessment for Drug Dependence and Alcoholism (SSADDA, n.d.).  The PTSD section 
of the SSADDA was used to collect data on 12 different types of traumatic experiences: 
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direct combat in a war; seriously physically attacked or assaulted; physically abused as a 
child; seriously neglected as a child; raped; sexually molested or assaulted; threatened 
with a weapon; held captive or kidnapped; witnessed someone being badly injured or 
killed; involved in a flood, fire, or other natural disaster; involved in a life-threatening 
accident; suffered a great shock because one of these events happened to someone close 
to you; and other (Xie et al., 2009).    
The SSADDA tool uses a number of questions that identify symptoms associated 
with PTSD (Pierucci-Lagha et al., 2005; SSADDA, n.d.).  Participants responded with 
“yes” or “no” when answering the questions.  These questions operationalized PTSD 
symptoms.  Examples of questions are noted below:      
Re-Experiencing/Intrusions 
O2 Did memories, visions, thoughts, or feelings about (EVENT) often keep 
coming to your mind even though you didn’t want them to? 
O4 Did you ever suddenly act or feel as if the (EVENT) was happening again?  
This may include flashbacks, or hallucinations, even if they occur when you 
are just waking up. 
Avoidance/Numbing 
O8 Did you ever try to avoid thinking about or having feelings about (EVENT) 
and find that you couldn’t? 
O9 Did you ever avoid activities, places, or people that reminded you of 
(EVENT)? 
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O12 During that period of time, did you feel more cut off, distant, or separated 
from people than before the (EVENT) happened?  
O13 Were there times when you believed you had lost the ability to experience 
emotions that you had before (EVENT) happened?   For example, did you feel 
you couldn’t have loving feelings or anything like that?  
O14 Were there times when you felt that there was no point in planning for the 
future—that you might not have a rewarding career; a happy family; or a long, 
good life?  
Hyper Arousal 
06 Did things that remind you of the (EVENT) make you sweat, tense up, breathe 
hard, tremble, or respond in some other physical way? 
O19 Were there times when unexpected noise, movement, or touch startled you 
more than before (EVENT)? 
O20 Were you more watchful or extremely aware of things around you? For 
example, were you more aware of certain sounds, smells, or sights?   
The SSADDA has questions specific to sleep and memory.   
Sleep 
O3 Did you have unpleasant dreams again and again about (EVENT)? 
O16 Did you have more trouble falling asleep or staying asleep than before 
(EVENT)? 
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Memory 
O10 Did you find that you sometimes could not remember important things about 
(EVENT)? 
The SSADDA collected information related to alcohol and drug usage while 
experiencing symptoms.  These questions were identified as the questions that would be 
used in the second phase of analysis to control for alcohol and drug abuse in this 
population.  Specifically, on Question O21 Participants responded “yes—clean” were 
included in the response.   
Alcohol and Drug-Related Questions 
O21 You have told me about things such as reliving the event through dreams, 
memories, or feelings; avoiding things that reminded you of the event; and 
problems with sleep, mood, or thinking.  Did these experiences last longer 
than 1 month? Participants responded “Yes —clean were included in the 
response.  
Additionally, participants responded with a “no” on the two questions below related to 
alcohol and drug use.   
Clustering at onset. 
A. Around the time you first had these very intense feelings, were you having 
experiences from three or more boxes found on this (ALCOHOL/COCAINE/ 
OPIATES/OTHER DRUG) sheet?   
Heavy use when not clustering 
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B. Around the time you first had these very intense feelings, were you (drinking 
heavily, using DRUGS) daily or almost daily? 
Assumptions 
Cooley, Clark, and Page (2011) identified a number of problems associated with 
data accuracy, including imputation errors when data are entered, differing algorithms 
being used, genotyping error rates due to duplication, and phenotype misclassification.  
Errors can also occur at the point of diagnosis (sensitivity and specificity; Cooley et al., 
2011).  This dissertation involved an assumption that the NCBI genetic database 
accurately diagnosed PTSD and that initial data collection techniques were completed 
accurately.  Bias and confounding may be minimized in association studies according to 
Botto and Khoury (2004), as recall bias is minimized and genotypes are stable over time.  
Refer to Chapter 3 for additional discussion of the nature of the study, specific research 
questions, hypotheses, and research objectives. 
Scope and Delimitations 
The SSADDA is a tool developed to study genetic association involving cocaine 
and opioid dependence (Pierucci-Lagha et al., 2005).  The SSADDA tool was originally 
developed from the Semi-Structured Assessment for the Genetics of Alcoholism 
(SSAGA); a free copy of the tool is available at http://genetics.bumc.bu.edu/ssadda/ 
(Boston University, n.d.).  “The SSADDA provides extensive coverage of the physical, 
psychological, social, and psychiatric manifestations of cocaine and opioid abuse and 
dependence in addition to a number of related Axis I and Axis II disorders” (Samet, 
Waxman, Hatzenberger, & Hasin, 2007, p. 28). 
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Pierucci –Lagha et al. (2005) examined inter rater reliability and test-retest 
reliability for the SSADDA using 293 participants in two sub studies.  For the PTSD 
section of the tool, they found inter rater reliability rates to be fair (k = 0.59, 95% CI 
0.40-0.77; Y = 0.73) and test retest reliability to be k = 0.76 (95% CI 0.53-0.99), Y = 0.88.  
PTSD was the only diagnosis whose prevalence rates increased between the test and 
retest period (p = 0.041; Pierucci-Lagha et al., 2005).  The SSADDA tool has been used 
in studies related to genes and PTSD; Xie et al. (2009) studied interactive effects of 
PTSD, childhood adversity, adult trauma, gene (5 HTTLPR region), and gene 
environment interactions.  Douglas et al. (2010) used the SSADDA to evaluate adverse 
childhood experiences (ACE) as risk factors for substance abuse.  Ford et al. (2009) used 
the SSADDA to evaluate comorbid psychiatric and substance disorders treatment use in 
the context of several groups diagnosed with cocaine dependence.  Thavichachart et al. 
(2009) used the SSADDA to identify the presence of chronic PTSD following the 
December 2004 tsunami off the Andaman coast in Thailand.  The SSADDA has been 
used to study attention deficit hyperactivity disorder, substance abuse disorders, in 
genome-wide association studies on substance abuse disorders, and in a genome-wide 
association study on PTSD (Arias et al., 2008; Gelernter et al., 2006; Xie et al., 2013).  
 Walker and van der Helm’s (2009) theory reviewed under the theoretical 
framework was chosen as the framework for this research because of its focus on sleep as 
the mechanism for PTSD development.  There are several other theories that were not 
chosen as the theoretical framework; these theories, which suggest that PTSD develops as 
a result of different experiences, are briefly reviewed.  Stress theory (residual or stress 
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evaporation) suggests that PTSD develops from the conflicts of war (Donovan, Padin-
Rivera, Dowd, & Blake, 1996).  Residual stress theory indicates that exposure to combat 
is a sufficient traumatic experience to explain the development of PTSD in veterans 
(Donovan et al., 1996).  Stress evaporation theory focuses on experiences that occur prior 
to war as the main predictor of individuals being more vulnerable to PTSD or chronic 
PTSD following a combat-related experience (Donovan et al., 1996).   
Trauma theory indicates that when individuals experience a significant threat or 
perceived threat to their lives, they experience biological, psychological, and social 
changes that may be helpful to them at the time but can have long term effects if not 
adequately treated (Bills, 2003).  Frans et al. (2005) suggests that PTSD develops from 
fear conditioning and may be a mechanism for the differences noted between genders.  
Genetic factors or neurobiological differences that occur in the neurotransmitters 
dopamine and serotonin and in thrombocyte monoaminooxidase activity may play a role 
in fear conditioning (Garpenstrand, Annas, Ekblom, Oreland, & Fredrikson, 2001, as 
cited by Frans et al., 2005).  One or several of these theories may be implicated in the 
etiology of PTSD.  These theories have been provided for reference only, but none of 
these theories implicate a symptom of PTSD as a pathway for its development and 
therefore were not chosen for the theoretical framework. 
In 1999, the United States Preventative Services Task Force developed criteria for 
evaluating internal validity for individual case control studies (National Center for 
Biotechnology Information U.S. National Library of Medicine [NCBINLM], n.d.).  The  
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criteria indicated a study has good internal validity if it includes: valid selection of cases, 
exclusion criteria applied equally to cases and controls, an 80% response rate, the same 
measurements applied to cases and controls, and addresses confounding variables     
(NCBINLM, n.d.).  These criteria evaluated internal validity.   
Considerations that focused on external validity included: selection of cases and  
controls, the country participants were selected from (in this case, cases and controls were 
African Americans and Europeans), eligibility and exclusion criteria, severity of illness,        
race, and measurement tool outcomes (Rothwell, 2005).  Prevalence rates of PTSD differ          
by race.  Lifetime prevalence of PTSD in European countries (Belgium, France, Germany,    
Italy, Netherlands, and Spain) was 1.1% (95% CI 1.0-1.3) to 1.9% (95% CI 1.7-2.1)         
(Alonso et al., 2004; Darves-Bornoz et al., 2008).  Alonso et al. (2004) indicated          
prevalence rates for PTSD in Europeans over the past twelve months was 0.9% (95%                
CI 0.7-1.1).  African Americans had lifetime prevalence rates of 8.7% compared to Whites 
whose rates were 7.0-7.4%; African Americans were also less likely to seek treatment for     
PTSD (Roberts, Gilman, Breslau, Breslau, & Koenen, 2011).  Boscarino, Kirschner,      
Hoffman, and Ehrlich (2013) used the New York PTSD Risk Score [NYPRS], core    
psychosocial measures, and genetic alleles (COMT-rs4680; FKBP5-rs9470080; CHRNA5-
rs16969968; CRHR1-rs110402) in a prediction model of PTSD and found by adding          
genetic allele’s sensitivity increased to 100% and specificity increased to 95.6%.                  
Long-term prevalence rates in the population studied by Boscarino et al. (2013) was 14.3%  
(95% CI – 11.1-11.8) and current PTSD was 10.7% (95% CI – 7.9-14.1).  These prevalence        
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rates are provided for comparison purposes for this research study.  The results from this 
dissertation should not be generalized beyond the population under study.  
Significance 
The implications for positive social change include understanding the genetic 
determinants of PTSD, which may lead to expanded pharmacological avenues for 
exploration, prevention, early intervention, and more effective treatment for individuals 
who develop PTSD (Koenen, 2007).  This dissertation brought attention to the research 
community of the genetic risk factors associated with PTSD, an area that has not received 
as much attention as other more prominent mental health conditions such as depression or 
schizophrenia and identified methodological concerns with the GWAS method 
(Cornelius, Nugent, Amstadter, & Koenen, 2010).  With many veterans returning to the 
United States following the recent war, the importance of effective PTSD diagnosis and 
treatment is in the forefront of public health.  A study of the whole genome may identify 
additional correlations previously undiscovered, which could generate additional research 
areas or topics for future research (Cornelius et al., 2010).  Additionally, this research 
contributed to the framework for GWA studies on PTSD.    
Summary 
The goal of this research was to study the genomes of individuals with PTSD and 
controls to identify whether genetic determinants that may be associated with PTSD and 
specifically to examine how sleep may be involved with the development of PTSD.  
Zondervan and Cardon (2007) indicated that identifying genetic variants, even those “that 
result in a low increased relative risk of a common condition may still have major public 
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health importance in terms of the number of people affected” (p. 2,492).  Chapter 2 
follows with a comprehensive review of the literature focusing on the research 
surrounding the genetic alleles and candidate gene studies of PTSD, the literature related 
to the symptoms of PTSD, the non-genetic research related to sleep difficulty and PTSD, 
and the literature on GWAS to date.  Additional evidence for confounding variables, 
moderator, and predictor variables is included in the review.   
Chapter 1 began with the introduction followed by the problem statement and 
purpose of the study.  The research questions and theoretical framework were reviewed, 
followed by the nature of the study, definitions, scope, delimitations, and limitations.  
The chapter concluded with a review of the significance of the study and a summary of 
the research idea.  Chapter 2 provides a comprehensive review of the literature from 2001 
to the present.  Additional evidence for confounding, moderator, and predictor variables 
is included in the review.  Chapter 3 focuses on the research design, including 
information about the database, sample size, power, and genome-wide association study 
method.  Chapter 4 focuses on the database used, variables, methods, and a 
comprehensive data analysis.  The research questions are also answered in this chapter.  
Chapter 5 contains an interpretation of the findings of the genome-wide study in the 
context of the literature reviewed in Chapter 2 and the theory used for the research study.  
Limitations of the study as well as recommendations for further research are included in 
Chapter 5.  The chapter ends by highlighting social change implications and the 
conclusion to the research.    
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Chapter 2: Literature Review 
Introduction  
Recommendations from the literature on PTSD identified that a genome-wide 
association study was needed to fill a gap in the literature (Cornelius et al., 2010; 
Feodorova & Sarafian, 2012; Norrholm & Ressler, 2009).  Although GWAS had been 
completed, there had been no GWAS to discover whether an association existed between 
genetic alleles and sleep difficulty.  The purpose of this study in the initial analysis phase 
was to discover whether a new genetic risk factor could be identified in individuals with 
PTSD or whether results from prior GWAS could be replicated in a different sample.  For 
any gene that reached genome-wide significance in the initial analysis, a second phase of 
analysis was planned that examined the genetic allele(s) and the symptoms associated 
with PTSD and the specific sub symptom of sleep. 
Prevalence rates indicate that only a portion of individuals develop PTSD, 
suggesting a genetic component to the disorder (Koenen, 2007; Yehuda et al., 2011).  A 
study by Bailey et al. (2010) examined heritability of PTSD and the symptoms associated 
with PTSD and found support for heritability for B, C, and D cluster symptoms.  
Heritability of PTSD was 0.37.  Bailey found PTSD symptom clusters had heritability of 
0.75 for B symptoms (re-experiencing/intrusion) and 0.39 for both C symptoms 
(avoidance/numbing) and D symptoms (hyper arousal).  Sleep is considered part of the D 
cluster of symptoms.  Recommendations from the literature supported further study of the 
potential link between PTSD and sleep as a potential pathway for PTSD development 
(Krakow, German, et al., 2001; Krakow, Hollifield, et al., 2001; Walker & van der Helm, 
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2009; Yetkin et al., 2010).  Sleep difficulties (in the form of insomnia, poor sleep quality, 
and nightmares) are reported by 70-91% of individuals diagnosed with PTSD (APA, 
2000; Maher et al., 2006). Studies focused on treating sleep problems have resulted in 
improvements in sleep functioning, symptoms of posttraumatic stress disorder, and 
cognitive functioning (particularly long-term verbal memory; Krakow, Germain, et al., 
2001; Krakow, Hollifield, et al., 2001; Raboni et al., 2009; Ulmer et al., 2011).   
Walker and van der Helm’s (2009) “sleep to remember sleep to forget” hypothesis 
suggests that sleep is not a symptom of PTSD but rather a causal factor for its 
development.  Stickgold (2002) has suggested that PTSD develops as a function of 
neurotransmitter failure or disruption preventing normal integration of memory 
processes.  This memory processing occurs during sleep; “posttraumatic re-enactments 
(in the form of nightmares or dreaming) are understood as a psychological correlate of 
pathological changes to normal brain functioning during (REM) sleep” (Wittman, 2007, 
p. 4).  Four genome-wide association studies on PTSD have been published, with one 
study lending support for further study of PTSD and sleep difficulty (Guffanti et al., 
2013; Logue et al., 2012; Solovieff et al., 2014; Xie et al., 2013).  Logue et al. (2012) 
found SNP rs8042149 in the retinoid-related orphan receptor alpha gene (RORα) 
associated with PTSD.  The RORα gene is thought to be involved in circadian rhythm 
functioning and in the circadian clock (Akashi & Takumi, 2005).   
Past genetic research on PTSD has focused on individual candidate gene studies; 
these studies have found a number of individual genes associated with PTSD (Amstadter 
et al., 2011; Change et al., 2012; Dragon & Onisczenko, 2009; Goenjian et al., 2012; 
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Hauer et al., 2011; Lee et al., 2005; Morey et al., 2011; Ressler et al., 2011; Sarapas et al., 
2011; Segman et al., 2002; Voisey et al., 2010).  While these studies have advanced the 
understanding of potential genetic risk factors, other studies have found no association or 
mixed results (Bailey et al., 2010; Mellman et al., 2009; Morgan et al., 2003; Pivac et al., 
2006; Sah et al., 2009).   
Chapter 2 begins with a review of the literature search strategy followed by the 
theoretical foundation that provides the basis for the study.  The next section contains a 
review of how researchers have approached the topic in the past, including collection 
techniques, measurement tools, and common statistical techniques, followed by a review 
of the genetic alleles identified in the literature (i.e., glucocorticoid, dopamine, 
gluterameric, and serotonin systems).  The literature review continues with a review of 
the few studies that have examined genetic alleles and the symptoms associated with 
PTSD.  The genetic allele COMT has been implicated in both sleep and PTSD is 
reviewed, leading into the next section that provides the non-genetic literature showing 
the relationship of sleep and PTSD.  The chapter concludes with literature on the GWAS 
method and a review of the current GWAS studies with a transition to Chapter 3. 
Literature Search Strategy  
The literature review involved using the Academic Search Premier database with 
a focus on scholarly, peer-reviewed journals (articles 2001-present) with word search 
terms PTSD, genes, and genetics.  One hundred fourteen articles were reviewed from this 
search.  Other keyword terms, PTSD, genes or genetics, and sleep, were also used.  This 
search yielded only two results.  PTSD and epigenetics yielded 22 results.  Key terms 
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PTSD + epidemiology + sleep disorder yielded 501 results.  Additional Academic Search 
Premier searches were done to review PTSD+allele and PTSD+single nucleotide 
polymorphism”, which yielded an additional 74 results that were reviewed.  Google 
Scholar was searched with the terms GWAS, “PTSD, and epidemiology.  Results yielded a 
total of 284 additional articles.  Additional literature search terms included PTSD, gene, 
and each symptom of PTSD (re-experiencing [two articles], hyper arousal [three 
articles], and avoidance [three articles]).  There were no articles found related to GWAS 
and PTSD symptoms.  There were no articles related to GWAS, PTSD, and sleep.  
Reference articles used by other researchers were further investigated for their relevance.  
I subscribed to the National Center for Biotechnology Information (NCBI) at the U.S. 
National Library of Medicine (NLM) to obtain the most recent articles published related 
to posttraumatic stress disorders and genes.  
The literature related to potential genes associated with PTSD includes candidate 
gene association studies, single nucleotide polymorphs (SNP) studies, haplotype studies, 
linkage studies, GWAS, and twin studies.  Twin studies were not included in this 
literature.  Gene expression studies (epigenetic studies) were excluded in this review 
unless the gene studied was directly associated or no association was found with PTSD 
and the gene was not acting as a modifier or had an interaction affect.  Studies outside of 
the United States were included. 
Theoretical Foundation—Walker’s “Sleep to Forget, Sleep to Remember” (SFSR)  
Various theories were reviewed in the introduction; however, none of the theories 
reviewed identified a symptom or symptoms of PTSD as a possible pathway.  The fear 
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conditioning theory was considered for this dissertation; however, the focus of the theory 
is related to the structure(s) in the brain (amygdala) involved in fear and not believed to 
be related to a specific symptom of PTSD.  Walker’s (2009) ”sleep to forget sleep to 
remember” (SFSR) hypothesis focuses on the specific symptom of sleep and therefore 
was chosen.  Walker (2009) suggested that sleep is involved in the processes the brain 
uses to initially store events as memories (referred to as encoding) and in the process 
used to maintain those memories (known as memory consolidation).  Sleep deprivation 
may play a role in memory, particularly for memories with emotional content (Walker, 
2009).  Walker stated,  
the impact of sleep loss on basic emotional regulation and perception has received 
limited research attention … the absence of research is striking considering that 
nearly all psychiatric and neurological mood disorders express co-occurring 
abnormalities of sleep, suggesting an intimate relationship between sleep and 
emotion. (Walker & van der Helm, 2009, p. 738)  
Walker (2009) suggested that the inability to discharge negative, emotionally laden 
memories combined with the inability to properly retain positive or neutral memories 
may be an avenue of study for emotional problems that have co-occurring sleep issues. 
Walker and van der Helm (2009) suggested that this framework may be specifically 
relevant to major depression disorder and PTSD, both known to have co-occurring sleep 
problems (i.e., insomnia or nightmares) associated with them.  Figure 2 indicates how 
this framework might be applied.   
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This “sleep to forget sleep to remember” hypothesis by Walker (2009) is a new 
model related to sleep and emotion that is being developed and has not been widely 
applied in the literature.  In an unpublished study reviewed in Walker, sleep deprivation 
and retention of positive, negative, and neutral words were studied.  Walker found that 
sleep deprivation (38 hours total) resulted in 60% retention in memories.  In those that 
were sleep deprived, neutral and positive words were not retained; however, negative 
words were not affected by sleep deprivation.  Walker suggested that people “sleep to 
forget” and also to remember based on the observation that initially memories may 
contain significant emotion associated with them but over time, as memories are recalled, 
there is less emotion associated with the memory (p. 189).  This emotion acts like a 
“blanket” around a memory that is removed over time with only the factual information 
retained, with REM sleep being the conduit for this process (p. 189).  In another study by 
Walker (2011), the amygdala of individuals was less reactive in response to emotional 
stimuli following a night’s sleep compared to individuals who did not sleep.   
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Figure 2. Sleep to forget sleep to remember (SFSR) framework.  
The sleep to forget and sleep to remember (SFSR) model of emotional memory 
processing: (a) Neural dynamics. Waking formation of an episodic emotional 
memory involves the coordinated encoding of hippocampal-bound information 
within cortical modules, facilitated by the amygdala, and modulated by high 
concentrations of aminergic neurochemistry. During subsequent REM sleep, these 
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same neural structures are reactivated, the coordination of which is made possible 
by synchronous theta oscillations throughout these networks, supporting the 
ability to reprocess previously learned emotional experiences. However, this 
reactivation occurs in a neurochemical milieu devoid of aminergic modulation 
and dominated by cholinergic neurochemistry. As a consequence, emotional 
memory reprocessing can achieve, on the one hand, a depotentiation of the 
affective tone initially associated with the event(s) at encoding, while on the 
other, a simultaneous and progressive neocortical consolidation of the 
information. The latter process of developing stronger cortico-cortical 
connections additionally supports integration into previous acquired 
autobiographical experiences, further aiding the assimilation of the affective 
event(s) in the context of past knowledge, the conscious expression of which may 
contribute to the experience of dreaming. Cross-connectivity between structures is 
represented by number and thickness of lines. Circles within cortical and 
hippocampal structures represent information nodes; shade reflects extent of 
connectivity: strong (filled), moderate (grey), and weak (clear). Color fill of 
amygdala and arrow thickness represents magnitude of co-activation with and 
influence on the hippocampus. (b) Conceptual outcome. Through multiple 
iterations of this REM mechanism across the night, and/or across multiple nights, 
the long-term consequence of such sleep-dependent reprocessing would allow for 
the strengthening and retention of salient information previously tagged as 
emotional at the time of learning. However, recall no longer maintains an 
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affective, aminergic charge, allowing for post-sleep recollection with minimal 
autonomic reactivity (unlike encoding), thereby preventing a state of chronic 
anxiety. (Walker & van der Helm, 2009, p. 742.  Reprint permission obtained 
November 19, 2012, from Mr. Walker) 
Past Research Approaches to PTSD 
Researchers have approached the study of genetic risk factors for PTSD primarily 
through studies of genetic alleles or candidate gene studies.  Collection methods of 
genetic material for candidate gene studies have been through saliva and blood samples 
(Kolassa, Ertl, et al., 2010; Kolassa, Kolassa, et al., 2010; Sayin et al., 2010).  Methods of 
identifying genes have included genotyping, genotyping and functional MRI imaging 
(fMRI), and polymerase chain reaction (Lee et al., 2005; Lee et al., 2006; Mellman et al., 
2009; Morey et al., 2011; Sah et al., 2009; Segman et al., 2002; Voisey et al., 2009).  
Walden University does not allow for original data collection of biological material; 
therefore, a database was sought that had already completed the collection and 
genotyping of the genomic data.   
Measurement tools used in the literature to examine PTSD have included the 
Clinician Administered PTSD Scale (CAPS), the Post Traumatic Stress Diagnostic Scale, 
the PTSD Checklist (PCL), the Mississippi Scale for combat-related PTSD, the PTSD-F 
and PTSD-C, the Structured Clinical Interview for DSM-III-R (SCID), the Korean 
version of the SCID, the UCLA PTSD Reaction Index, , the Davidson Trauma Scale
TM
, 
and the Semi Structured Assessment and Drug Dependence and Alcoholism (Blake et al., 
1995; Chang et al., 2012; Davidson, 1997; Douglas et al., 2010; Dragan & Oniszczenko, 
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2009; Foa, 1996; Foa, Cashman, Jaycox & Perry, 1997; Ford et al., 2009; Goenjian et al., 
2012; Lee et al., 2005; Keane, Caddelle, & Taylor, 1998; Kolassa, Ertl, et al., 2010; 
Kolassa, Kolassa, et al., 2010; Mellman et al., 2009; Morey et al., 2011; Pivac et al., 
2006; Pivac et al., 2007; Pynoos, Rodriguez, Steinberg, Stuber, & Frederick, 1998; Sah et 
al., 2009; Sarapas et al., 2011; Sayin et al., 2010; SSAADDA, n.d.; Spitzer, Williams, 
Gibbon, & First, 1992; Steinberg, Brymer, Decker, & Pynoos, 1998; Weathers, 1993; 
Weathers, Litz, Huska, & Keane, 1994; Voisey et al., 2009; Xie et al., 2009; Xie et al., 
2013).   
Statistical procedures in the literature consist of many different approaches.  
Candidate gene studies consistently ensure that groups are in Hardy Weinberg 
equilibrium (Chang et al., 2012; Dragan & Oniszczenko, 2009; Hauer et al., 2011; Lee et 
al., 2005; Lee et al., 2006; Morey et al., 2011; Pivac et al., 2007; Sarapas et al., 2011; 
Segman et al., 2002; Voisey et al., 2009).  Bonferri correction was used to account for 
multiple testing (Sarapas et al., 2011; Xie et al., 2010).  The Nyholt correction was used 
by Morey et al. (2011).  Other statistical tools used have included the following: 
ANOVA, the two-way ANOVA, the MANCOVA logistic regression, chi square, t test, 
and x
2
 (Dragan & Oniszczenko, 2009; Kolassa, Kolassa, et al., 2010; Lee et al., 2005; Lee 
et al., 2006; Martel et al., 2012; Morgan et al.; 2003; Pivac et al., 2006; Pivac et al., 2007; 
Ressler et al., 2011; Sarapas et al., 2011; Sah et al., 2009; Segman et al., 2002; Voisey et 
al., 2009;Voisey et al., 2010; Xie et al., 2010).  Less used tools included the Mantel-
Haenszel test, odds ratio (OR), population attributable fractions, attributable risks, and 
general linear modeling (Morey et al., 2011; Voisey et al., 2009).   
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Studies examining sleep and PTSD have used different measurement instruments 
including in-home polysomnography and actigraphic recording (Germain et al., 2004; 
Klein, Koren, Arnon, & Lavie, 2003; van Liempt, Westenberg, Arends, & Vermetten, 
2011).  Measurement tools have included the Pittsburg Sleep Quality Index (PSQI), the 
UCLA PTSD Reactive Index, the Impact Event Scale, and the Patient Checklist (PCL) 
for PTSD (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989; Gellis, Gehrman, 
Mavandadi, & Oslin, 2010; Germain et al., 2004; Horowitz, Wilner, & Alvarez, 1979; 
Langston, Davis, & Swopes, 2010; Lewis, Creamer, & Failla, 2009; Pynoos et al., 1998; 
Weathers, 1993; Weathers et al., 1994).  Consistent with PTSD studies, statistical 
techniques used in studying sleep and PTSD have included the t test, ANOVA, 
MANOVA, logistical regression, and meta analyses (Gellis et al., 2010; Klein et al., 
2003; Liempt et al., 2010; Lewis et al., 2009). 
GWA studies have been used to examine a number of physical health conditions 
(diabetes, obesity, Crohn’s disease, ulcerative colitis, multiple sclerosis, HDL, and 
several other medical conditions) as well as behavioral health conditions such as 
schizophrenia and bipolar disorder (Visscher, Brown, McCarthy, & Yang, 2012).  The 
four GWA studies on PTSD have all used PLINK software and logistic regression 
(Guffanti et al., 2013; Logue et al., 2012; Solovieff et al., 2014; Xie et al., 2013).  
Chapter 3 contains further description of the measurement tools and statistical techniques.   
Candidate Gene/Genetic Allele Literature 
Information in this section addresses Research Question 1 and reviews the 
candidate gene literature on PTSD.  
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Genetic Alleles of the Serotonin Transporter Region  
Mellman et al. (2009) examined the HT2A and the SLC6A4 in the 5HTTLPR 
(serotonin transporter region) in an African American population and found that being 
female with a traumatic sexual experience and depression were significantly associated 
with a diagnosis of PTSD; however, no association was found with the SLC6A4 gene.  
Mellman et al. indicated that although the sample size had sufficient power to detect for a 
general, allelelic, or recessive model, it did not have sufficient power to detect for a 
dominant model, which may be why an association within the SLC6A4 in the 5HTTLPR 
region was not found.  Goenjian et al. (2012) examined the SLC6A4 in earthquake 
survivors and also found no association.  These results contradict a study by Thakur, 
Joober, and Brunet (2009) that found an association with “ll” homozygotes individuals 
with the SLC6A4 gene in post-motor vehicle accident victims.  At both 1 month and 12 
months, “ll” homozygotes had a greater percentage of PTSD development; 82% at 1 
month for acute PTSD and 55% at 12 months for chronic PTSD (Thakur et al., 2009).  At 
the 12-month time period, the “ll” homozygote for the PTSD group had an odds ratio of 
4.8 compared to the “ss” and “sl” genotype.  Thaker et al. indicated that the “s” allele 
has been shown to be a risk factor in other studies and should be evaluated to determine if 
it is a risk factor or a protective factor. 
Morey et al. (2011) examined the SLC6A4 gene in trauma exposed PTSD cases 
and trauma exposed controls.  Functional MRI (fMRI) recorded cases and controls as 
they were engaging in tasks related to working memory (viewing three faces over a 
specific period of time) while experiencing combat scenes (negative emotion), non-
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combat scenes, or scrambled pictures, which were controls (Morey et al., 2011).  Cases 
and controls were then engaged in a retrieval phase of one of the faces while brain 
activity was compared (Morey et al., 2011).  Morey et al. found certain SNPs activated 
areas of the brain when the pictures were viewed when comparing cases to controls.  
Specifically, SNP rs16965628 with a “GG” genotype in the SLC6A4 activated the 
ventrolateral PFC in PTSD patients viewing combat scenes with a delay in working 
memory.   When examined by race, the SNP rs1696528 in African Americans with PTSD 
was significant compared to controls but this was not observed in European Americans 
(Morey et al., 2011).  Morey et al. suggested that this SNP may be a moderator variable.  
Morey et al. examined the amygdala focusing on the biallelic, “S” allele carriers (s/s or 
l/l) and found the left region of the amygdala for “S” allele carriers to be more active in 
PTSD cases compared to controls when viewing combat distracter scenes.  There was no 
association noted for the “ll” genotype.   
Mellman et al. (2009) found that the “G” allele in the 5HTR2A region of the 
serotonin transporter predicted PTSD.  Another area of the serotonin transporter promoter 
gene, the polymorphism region (SERTPR) located at 17q11-1-q12 was examined by Lee 
et al. (2005).  Significant differences were not found in genotypes (s/s or l/l) between 
cases and controls.  Allele frequencies (s or l) and “s/s” carriers were significantly 
different compared to “s/l” + “l/l”.  Lee et al. suggested that the “s” allele and the “s/s” 
genotype may be involved and increase susceptibility of PTSD.   
Goenjian et al. (2012) examined two isomophisms in 200 Caucasian, Armenia 
Spitak earthquake survivors from 12 multigenerational families thought to be involved 
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with the serotogonergic system: Tryptophan Hydroxylase 1 (TPH1) on chromosome 11 
and TPH2 on chromosome 12.  A significant association was found with PTSD and the 
”t” allele of TPH1, SNP rs2108977 accounting for 3% of the variance (Goenjian et al., 
2012).  Additionally, the “s” allele of the TPH2, SNP rs11178997 was associated with 
PTSD symptoms accounting for 4% of the variance (Goenjian et al., 2012).   
Limitations noted in these studies included: small sample sizes, low power, 
population-stratification bias, recall bias, lack of controlling for potentiating confounding 
variables such as sex, depression, sexual assault, gender, or for trauma exposure in 
controls leading to the possibility that some controls had the genetic vulnerability but did 
not have the trauma exposure to trigger possible development of PTSD, and results could 
not be generalized beyond the study population (Goenjian et al., 2012; Lee et al., 2005; 
Mellman et al., 2009; Morey et al., 2011; Thaker et al., 2009).    
Brain-Derived Neurotrophic Factor (BDNF) 
Lee et al. (2006) examined brain derived neurotrophic factor (BDNF) gene 
Val66Met polymorphism.  The BDNF gene is involved in the hypothalamic-pituitary-
adrenal axis area of the brain and thought to be important in modulating stress (Lee et al., 
2006).   The Val66Met polymorph was grouped in two categories: Met66 allele (Met/Met 
and Met/Val) or the Val/Val genotype.  Lee et al. compared the genotype and allele 
frequencies of 107 PTSD cases and 161 controls in a Korean population.  No association 
was found for the Met66 or the Val/Val genotype.  Limitations of this study included: 
small sample size, possibility of population stratification bias, other variants of the BDNF 
gene not studied may have contributed to PTSD, and exposure to trauma was not a 
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variable controlled for in the study; therefore controls may have carried a genotype or 
allele frequency making any association difficult to detect (Lee et al., 2006).   
Glucocorticoid Receptor Pathway  
van Zuiden et al. (2012) examined pre-existing vulnerability factors for PTSD in 
448 male, Dutch Armed Forces soldiers deployed to Afghanistan prior to and 6 months 
after deployment.  Vulnerability factors included pre-deployment expression of GR target 
genes (FK Binding Protein 5, GILZ, and SGK1), cortisol levels, and childhood trauma.  
Of the 448 soldiers, 35 developed PTSD symptoms following return from deployment 
with 413 soldiers serving as the control group.  Cases had significant predeployment and 
post deployment PTSD symptoms compared to the control group.  Deployment increased 
PTSD symptoms in cases but not in controls.  Interaction effects were noted for cases 
with self-reported symptoms of depression, anxiety, and sleep disturbances compared to 
controls.  After deployment, independent associations were found with PTSD and the 
following variables: pre-deployment glucocorticoid receptor number, low FKBP5 mRNA 
expression, high GILZ mRNA expression, and childhood trauma.  PTSD and SNP 
associations were not able to be evaluated due to the small sample size.   
Sarapas et al. (2011) examined survivors of 9/11 with and without PTSD.  The 
sample consisted of 20 cases with lifetime PTSD compared to 20 controls matched by 
similar exposure (high, low, or indirect), age, gender, and race.  Signal transducer and 
activator of transcription 5B (STAT5B) and Nuclear Factor I/A, two genes in the 
glucocorticoid receptor, reduced expression in PTSD cases.  Sarapas et al. further studied 
four SNPs in the FKBP5 region: rs3800373, rs9296158, rs1360780, and rs9470080 and 
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found “homozygosity for any of 4 PTSD risk-related polymorphisms at FKBP5 predicted 
FKBP5 expression, which mediated indirect effects of genotype on plasma cortisol and 
PTSD severity” (p. 101).  Xie et al. (2010) studied these same four SNPS in the FKBP5 
region in 1,143 European Americans (EA) and 1,284 African Americans (AA) and found 
no association in the FKBP5 region.  An association was found when the 4 SNPs and 
childhood adversity were entered into logistic regression; SNP rs9470080 moderated the 
effect of childhood adversity only and risk for PTSD in the AA population.  Following, 
Bonferroni correction, 3 SNPs (rs3800373, rs9296158, and rs9470080) remained 
significant with SNP rs9470080 having a continued moderator effect for PTSD risk when 
there was exposure to childhood adversity (Xie et al., 2010).  No effect was noted for the 
EA population.   
Additional analyses focused on risk of PTSD with childhood adversity and the 
FKBP5 region; rs9470080 polymorph was statistically significant (Xie et al., 2010).  
Interestingly, with rs9470080 in the AA population, individuals with the “TT” genotypes 
were less likely to develop PTSD compared to the “CC” or “CT” genotypes.  However, 
when individuals that had “TT” genotypes and had also experienced childhood adversity 
their risk for developing PTSD was greatest among the three groups (though not 
significant).  This was only noted in the AA population and not found in the EA 
population.  Xie et al. (2010) studied opioid, cocaine, and alcohol phenotype effects on 
the FKBP5 genotypes and childhood adversity as they relate to PTSD development.  
Only alcohol dependence was associated with risk for PTSD onset in the presence of the 
rs9470080 SNP and childhood adversity for both the AA and EA populations.  For EAs, 
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FKBP5 modified the effect of alcohol and cocaine on PTSD risk.  When modifiers were 
removed from the model, no interaction was noted for FKBP5 and childhood adversity 
and risk of PTSD among the EA population.  Xie et al. suggested possible reasons for the 
results of their study that found an effect in one population and not the other may be due 
to other variants interacting with SNPs in linkage disequilibrium, differences in allele 
frequencies that occur among different populations, different gene expressions, which 
may be related to other genetic factors, protective factors that were not identified in the 
present study, or interactions with other genes that were not identified in this study.   
Hauer et al. (2011) examined another section of the glucocorticoid receptor the 
Bc/l polymorphism.  Groups studied included: a homozygous carrier group, a second 
group that consisted of heterozygous Bc/l *G carrier, and non-carriers of Bc/I *G.  
Participants included 126 patients undergoing cardiac surgery followed by intensive care 
treatment.  Homozygous carriers had higher PTSD scores one week after surgery 
compared to the heterozygous and non-carrier group and remained higher but was not 
significant 6 months later.  Hauer et al. also found homozygous Bc/I *G carriers 
experienced more traumatic memories from ICU than the heterozygous and non-carrier 
group and had lower quality of life scores.  The limitation of Hauer et al.’s study was its 
low power.  Other limitations noted in studies related to the glucocorticoid receptor 
pathway included low statistical power due to the study design, small sample size, lack of 
classification of PTSD using DSM-IV criteria, recall bias of childhood adversity, and the 
type of adversity was not exhaustive (van Zuiden et al., 2012; Xie et al., 2010). 
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Gastrin-Releasing Peptide Receptor (GRP) and Stathmin 1 (STMN 1) 
Martel et al. (2012) studied stathim and gastrin-releasing peptide receptor 
(GRPR, “fear memory-related genes”) expression in mouse brains (p. 1).  Martel et al. 
studied the effect these genes had on fear extinction.  They initially used a technique to 
evoke a response.  Martel et al. found that if the same environment was present; a 
conditioned response can still occur despite efforts at extinguishing fear.  Martel et al. 
(2012) examined two different mice lines (knock out [KO] and wild type) along with 
controls.  In one mice line (GRPR), when neuronal activity was shifted from the 
prefrontal cortex (PFC) to the amygdala fear increased and extinction decreased (it took 
longer for fear to extinguish).  When the neuronal activity was shifted from the amygdala 
to the prefrontal cortex, the opposite was noted in stathmin mice, fear decreased and 
extinction increased (fear extinguished more rapidly).  Mice with GRPR exhibited 
freezing when the cue occurred.  GRPR mice froze 42% of the time, while KO mice froze 
62% of the time.  Martel et al. studied the two genotypes, GRPR and strathmin 
separately.  They found GRPR KO mice froze more often than the GRPR wild type.  
Fifteen days after the initial testing, GRPR KO mice still exhibited more freezing than the 
WT mice.  Mice with the stathmin genotype both knockout (KO) and wild type (WT) 
were similar in their freezing without significant differences noted.  A two way ANOVA 
found a difference between the two stathmin mice with KO mice freezing less often than 
WT mice.  Martel et al. noted this was related to a cue but not specific to context and 
suggested that additional research is needed.  
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Dopamine Transporter System (SLC6A3 (DAT 1) and Dopamine Transport  
Segman et al. (2002) studied SLC6A3 also known as dopamine active transporter 
(DAT1) in 102 Jewish Ashkenazi or non-Ashkenazi individuals with PTSD.  Control 
subjects (n = 104) were recruited from a hospital emergency department and exposed to a 
traumatic event but did not develop PTSD.   Segman et al. compared cases and controls 
on the SLC6A3 allele frequencies (9 repeat/9R and 10 repeat/10R) and the genotype 
frequencies and found that there were more 9 repeat alleles in cases compared to controls 
(43% compared to 30.5%).  Cases with the 9 repeat allele had an odds ratio of OR = 1.72 
(95% CI = 1.12-2.62).  Genotype distribution was also significantly different with the “9-
9” allele having a greater distribution (20.43%) in PTSD cases compared to controls 
(9.47 %); an increased odds ratio, 2.45, was also noted for the “9-9” allele (95%, CI = 
0.98-6.52).  Segman et al. suggested that the variable number of tandem repeats (VNTR) 
polymorphism may be how the dopamine transporter (DAT) gene is expressed through 
either linkage disequilibrium or mRNA transcription.  Results indicated that the DAT 
region was associated with an increased risk of PTSD that was not related to confounding 
or bias from population stratification (Segman et al., 2002).  Segman et al. suggested that 
a portion of the population may possess a risk for developing PTSD but trauma exposure 
is required for PTSD to develop.  Segman et al. suggested that there may be alleles, 
without the environmental trigger, that provide protective effects.      
Chang et al. (2012) examined the SLC5A3 (DAT1) in 62 PTSD cases and 258 
controls from a Detroit neighborhood.  Alleles were identified at: 3R, 7R, 8R, 9R, 10R, 
and 11R.  The greatest frequencies were found at the 10R (75.42%) and 9R (17.7%) for 
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all 362 participants.  When age, gender, socioeconomic status, race, smoking, number of 
traumatic events, and lifetime depression were controlled for in 9R and 10R,  odds ratio 
for individuals with PTSD with the SLC6A3 genotype 9R allele were similar to Segman 
et al. (2002) OR of 1.72 compared to 1.98 (Chang et al., 2012).                                                     
Pivac et al. (2006) examined dopamine beta-hydroxylase (DBH) in 93 Croatian 
war veterans hospitalized in an inpatient psychiatric setting diagnosed with chronic 
posttraumatic stress disorder (PTSD). Controls were 124 healthy males matched for age, 
gender, smoking, and other demographics. Significant differences were found between 
cases and controls in cortisol levels, thyroid levels, and lipid levels (higher cholesterol, 
lower HDL or good cholesterol, and higher triglyceride levels).  Results indicated plasma 
DBH and 5-HT was not significant between cases and controls.  
Voisey et al. (2009) examined three polymorphs:  SNP 957C>T, the deletion 
polymorphism -141delC in the DRD2 gene, and a SNP, Taq 1A, rs1800497 in 127 PTSD 
cases and 228 controls.  Voisey et al. found a significant association in the DRD2 region 
with the 957C>T polymorphism specific to the “C” allele.  The frequency of the “C” 
allele in PTSD patients was 51.7% compared to controls (42.5%).  The OR of having 
PTSD with the “C” allele was 1.45.  Voisey et al. found that individuals with PTSD were 
two times more likely to have the “CC” genotype compared to the “TT” genotype than 
controls.  The population attributable risk found 14% susceptibility for PTSD related to 
the “C” allele with the “CC” genotype (Voisey et al., 2009).  No association was found 
for the Taq1A or the -141delC polymorphism (Voisey et al., 2009).  Limitations included: 
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population stratification, a limited sample size, and p values that were not adjusted for 
multiple testing (Voisey et al., 2009).     
Dragan and Oniszczenko (2009) examined the dopamine receptor D4 exon III 
polymorphism (DRD4 gene) in 107 individuals exposed to massive flooding.  Groups 
were divided into low and high trauma exposure along with the number of their traumatic 
experiences (zero to six).  Dragan and Oniszczenko found that individuals with the long 
DRD4 variants (7R) had more intense PTSD symptoms (scored higher on scales 
measuring PTSD).  Significant correlations were also found between age and PTSD score 
intensity, number of previous traumas and PTSD score intensity, and gender and the 
intrusion/arousal (I/A) PTSD subscale (Dragan & Oniszczenko, 2009).  When examining 
main effects from the DRD4 genotype, type of trauma, and PTSD intensity while 
controlling for covariates (age, gender, and previous traumas) Dragan and Oniszczenko 
found a main effect of genotype with the avoidance/numbing (AN) subscale.  Limitations 
included: a small sample size, low power, and potential confounding variables such as 
alcohol use or tobacco use that were not controlled for in the study (Dragan & 
Oniszczenko, 2009).  The authors also indicate the measurement tools they used were not 
tools used in other research studies.     
Glutameric System 
Voisey et al. (2010) studied the dysbindin gene, DTNBP1 SNP rs9370822 in 250 
cases and controls in several psychiatric disorders including PTSD cases (127), opiate 
dependents cases (120), nicotine dependent cases (147), and alcohol dependent cases 
(231).  The DTNBP1 SNP rs9370822 allele was associated with PTSD, OR = 1.74 
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(Voisey et al., 2010).  This same allele association was noted for nicotine and opiate 
dependence (Voisey et al., 2010).  No association was found for alcohol dependence 
(Voisey et al., 2010).  Genotype associations (AA, AC, and CC) of DTNBP1 SNP 
rs9370822 differed among psychiatric disorders (Voisey et al., 2010).  Genotypes with 
“CC” had an OR of 3.14 for PTSD, compared to AC, OR = 1.93 and AA, OR = 1.00 
(Voisey et al., 2010).  Voisey et al. noted sample size was a limitation to their study.      
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 
Ressler et al. (2011) examined 44 single nucleotide polymorphisms (SNPs) of the 
PACAP (14 SNPs from ADCYAP1) and PAC1 (30 SNPs from ADCYAP1R1) region 
from 798 individuals (503 females and 295 males) who had experienced severe trauma.  
Ressler et al. found one significant association in SNP rs2267735, part of the 
ADCYAP1R1 receptor for females only.  The association was significant after correcting 
for multiple testing.  Ressler et al. replicated their findings in a second population of 439 
participants (260 females and 179 males).  They found SNP rs2267735 was associated 
with females in the second population.  When both populations were combined the 
association remained significant in females only.   
Monamine Oxidase (MAO) Intron 13 Polymorphism 
Pivac et al. (2007) studied monamine oxidase intron (MAO) 13 polymorphism (A 
to G change) in 386 Croatian, Caucasian, male participants.  Cases consisted of 106 war 
exposed combat veterans with current and chronic PTSD both with and without psychotic 
symptoms, 41 war exposed combat veterans without PTSD, and 242 healthy controls.  A 
two way ANOVA found no significant effect for genotype, though a significant effect 
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was found for nonsmoking, psychotic PTSD veterans with the “A” allele.  This group had 
higher platelet MAO activity than veterans without PTSD and “A” allele carriers, PTSD 
without psychosis and “A” allele carriers, and healthy controls with the “A” allele.  Pivac 
et al. suggested that the effect was related to the diagnosis of PTSD with psychosis rather 
than the “A” allele.  No effect was found for the “G” allele.   
Neuropeptide Y (NPY)  
Morgan et al. (2003) examined neuropeptide Y in two studies (A and B).  Study A 
examined if trauma alone or PTSD impacted NPY levels.  Participants included 8 healthy 
combat veterans without PTSD as the control group, 18 combat veterans with PTSD, and 
8 healthy controls.  ANOVA compared baseline plasma NPY levels of the three groups; 
the three groups differed significantly at baseline.  Combat controls and PTSD 
participants had similar baseline plasma levels while healthy controls had plasma levels 
that were 30% lower (Morgan et al., 2003).         
Study B consisted of 41 active military personnel that were involved in a special 
forces training course.  A negative association was found between the number of 
traumatic life-threatening events and baseline NYP levels.  No other associations were 
found.  Morgan et al. suggested that exposure to trauma rather than PTSD symptoms 
were related to lower NPY levels.  Lower NPY levels are thought to impact the 
flight/fight response experienced during extreme stress and may play some role in the 
development of PTSD (Morgan et al., 2003).  
Sah et al. (2009) examined NPY levels from 10 men with combat related chronic 
PTSD and 13 male controls.  Sah et al. found that PTSD cases had lower levels of CSF 
50 
 
 
NPY compared to healthy controls.  Sah et al. suggested that higher levels of CSF NPY 
may serve as a protective factor promoting resilience in some individuals.  The procedure 
for collecting CSF NPY samples involved a lumbar puncture procedure; the authors 
indicate the procedure itself could have been a difficult experience for some individuals 
however, if the procedure alone accounted for the lower levels observed, a similar level 
of CSF would have been found in controls.  Sah et al. indicated healthy controls were not 
exposed to extreme trauma therefore additional studies are needed.   
PTSD Symptoms 
This section addresses Research Question 2 and provides the candidate genes 
studies that have examined PTSD symptoms.  
Corticotropin-Releasing Hormone Receptor (CRHR1) 
Amstadter et al. (2011) studied eight SNPs from the corticotrophin-releasing 
hormone (CRH) receptor 1 gene.  PTSD symptom frequency was collected at 3, 12, and 
18 month intervals during a hospital stay; one SNP, rs12944712 was associated with 
PTSD symptoms.  This SNP, rs12944712, was further analyzed and found acute PTSD 
symptoms increased with the “G” alleles.  Amstadter et al. found that the more “G” 
alleles an individual had, the more rapidly PTSD symptoms decreased over time.   The 
authors suggested the decline in the “G” allele may be related to higher PTSD symptoms 
that then sharply decline.  A protective factor was found for rs1294412, minor allele “A”, 
for the level of symptoms that were collected at the acute hospital visit, which was not 
believed to be related to population stratification.  Acute PTSD symptoms were more 
prominent in females.  Violent injury was associated with a longer time frame of PTSD 
51 
 
 
symptoms.  Limitations included: the small sample size, inadequate power, attrition rates, 
results cannot be generalized, and population stratification (Amstadter et al., 2011).    
Thoeringer et al. (2012) studied the CRH receptor in mice.  They used fear 
conditioning to examine fear memories and hyper arousal in knock out and wild type 
mice.  The CRH receptor did not function properly allowing Thoeringer et al. to subject 
mice to an electric foot shock creating trauma memories.  Thoeringer et al. indicated this 
allowed the researchers to examine “associative learning accounting for intrusive 
memories and avoidance behavior, whereas non-associative (or stress related learning) 
results in hyper arousal” (Siegmund &Wotjak, 2006, as cited by Thoeringer et al., 2012, 
p. 788).  Thoeringer et al. found CRH impacted consolidation of memories in the first 
week but did not impact the retention of later recall of fear memories.  CHRHC1 
impacted remote memories.  KO mice that did not have CHRHC1 had less fear one 
month later.  The authors suggest blocking CHRC1 through pharmacological measures 
may impact the development of PTSD (Thoeringer et al., 2012). 
Dopamine System 
Bailey et al. (2010) examined the DRD2 and DAT gene in 200 Armenian 
earthquake survivors as well as cluster symptoms of PTSD (B-intrusion, C-
avoidance/number, and D-hyper arousal).  There were 39 participants that had the 
DRD2/A1+ allele; no association was found between the DRD2/A1+ allele and PTSD, 
total PTSD-RI score, B symptoms, or C symptoms.  D symptoms were not heritable 
based on analysis and were not considered for additional testing.  There were a total of 86 
participants with the DAT/9 repeat allele; no association was found for the DAT/9 repeat 
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allele and PTSD, total PTSD-RI score, B symptoms, or C symptoms.  Bailey et al. 
controlled for alcohol dependency for DAT participants and found no association.  
Limitations noted included: lack of generalizability beyond the Armenian participants, 
the sample size may have been too small to detect a small effect, and the results may only 
apply to chronic PTSD as the earthquake occurred in 1988 and acute symptoms may not 
have been present (Bailey et al., 2010).      
WFS1 Gene 
Kesner et al. (2009) examined the WFS1 gene in mice, specifically the 
glycoprotein Wolframin.  Several rats were housed together and then exposed to a 
predator scent (cases) compared to rats that were not exposed to the scent.  The rats 
freezing time and startle response (following exposure to a loud noise) were monitored 
and considered part of a hyper arousal response.  Cases were separated into PTSD-like 
symptoms and non-PTSD symptoms and treated either with citalopram or a saline 
solution. Controls were also divided into two control groups, one treated with citalopram 
and the other with saline solution.  Researchers were blinded in the study.  PTSD like 
behaviors developed in 16% of the rats, exhibiting symptoms from all three clusters 
above an established baseline.  PTSD like symptoms reduced after administering 
citalopram to PTSD-rats; Kesner et al. (2009) suggest the Wolframin gene may be a 
biomarker for PTSD.         
Hyper Arousal and Avoidance Symptoms: Serotonin Transporter System Region 
Sayin et al. (2010) conducted a prospective study with 77 Turkish individuals that 
suffered a trauma that focused on the 5 HTTLPR gene polymorphic region and Intron 2 
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(variable number of tandem repeats, VNTR).  The genotype that occurred most often in 
the 5 HTTLP region was “SL” (60%), followed by “LL” (24.4%) and “SS” was 15.6%.  
The “L” allele was three times (3:1) more likely to be present than the “S” allele.  In the 
VNTR polymorphism, the 12.12 repeat allele occurred most frequently (58.9%), the 
10.10 allele occurred 22.2% of the time and the frequency of the 12.10 was 18.9%.  The 
12 allele was also three times (3:1) more likely to occur compared to the 10 allele.  
Current PTSD was found in 23.3% of individuals and 50.0% had lifetime PTSD 
symptoms.  Further analysis only included lifetime PTSD individuals due to a small 
sample size with only current PTSD symptoms.  No association was found for severity of 
PTSD and gender, occupational status, marital status, psychiatric history, or the 
5HTTLPR and VNTR regions.  Both alleles with “higher activity", the “L” and the 12 
allele impacted symptoms associated with PTSD.  The “L” allele impacted hyper arousal 
symptoms with individuals having milder or less hyper arousal symptoms while the 12 
allele impacted the severity of avoidance symptoms.  Individuals with the “S” allele had 
more severe PTSD but this was not observed when other variables were controlled.  The 
“L” allele continued to be significant in its effect when other variables were controlled.  
Weaknesses noted for this study included the small sample size and the severity and type 
of trauma, which was physical trauma and considered "mild" (Sayin et al., 2010, p. 75).      
Hyper Arousal Symptoms Only: Pituitary Adenylate Cyclase-Activating 
Polypeptide (PACAP) 
Ressler et al. (2011) analyzed PTSD symptom clusters and genotype.  The “CC” 
genotype of rs2267735 in women was associated with total PTSD symptoms and hyper 
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arousal symptoms.  When other variables were controlled (childhood trauma, adult 
trauma, age, and race), the “CC” genotype was associated with hyper arousal symptoms 
compared to “G” carriers.  Ressler et al. further examined fear and startle response (hyper 
arousal symptoms) related to gender, genotype, and PTSD.  Females with PTSD and the 
“CC” genotype (rather than G genotype) of rs2267735 were less able to tell the difference 
between a conditioned stimulus and a safety stimulus and exhibited a greater startle 
response in the dark than in the light compared to men.  Ressler et al. suggested that this 
SNP may be implicated in why gender differences are noted between males and females 
in their PTSD symptoms.     
Re-Experiencing Symptoms Only: Apolipoprotein E Isoforms 
Freeman, Roca, Guggenheim, Kimbrell, and Griffen (2005) studied 
apolipoprotein (Apo) E alleles (apoE2, apoE3, and apoE4) in 54 Caucasian, combat 
related PTSD veterans.  Individuals with one allele (apoE4) were compared with other 
subjects; no association was found (Freeman et al., 2005).  An association was found for 
individuals with the apoE2 allele and the re-experiencing symptom of PTSD (Freeman et 
al., 2005).  Individuals with this allele scored lower on memory scores (Freeman et al., 
2005).  Limitations of this study included the small sample size and high psychiatric 
comorbidity (Freeman et al., 2005).  Olsen, Agam, Davis, and Raber (2012) also 
examined the ApoE isoforms (apoE2, apoE3, and apoE4) in targeted and wild type mice 
and found mice with apoE2 acquired and retrieved a fear response but were not able to 
extinguish the fear response. Wild type mice with apoE3 and apoE4 were able to 
extinguish the fear response.       
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PTSD and Sleep (Nongenetic Literature) 
This section reviews the literature for Research Question 3.  The literature focuses 
on one candidate gene that has been identified in PTSD and also in genetic literature 
related to sleep.  The remaining literature review focuses on the nongenetic literature 
establishing the relationship between PTSD and sleep related concerns.  The chapter 
concludes with the GWAS completed to date.   
Catechol-o-methyltransferase (COMT) 
Kolassa, Kolassa, et al. (2010) examined different genotypes (Val/Val, Met/Met, 
and Val/Met) of the catechol-o-methyltransferase (COMT) encoded on chromosome 
22q11.1-q11.2 with polymorphism at codon 158 and the interaction of traumatic load 
(defined as the number of different traumatic experiences not the frequency of witnessed 
or experienced events).  A total of 424 non-related Rwandese refugees participated.  
Results included dose-response relationship to prevalence rates for lifetime PTSD and 
traumatic load (i.e., the greater number of traumatic events the greater prevalence of 
lifetime PTSD).  Lifetime PTSD was impacted by genotype and traumatic load.  The 
greater the traumatic load the more likely an individual had experienced lifetime PTSD 
(Kolassa, Kolassa, et al., 2010).   
An effect was also found with the Met/Met genotype, traumatic load, and PTSD.  
There was a greater likelihood of developing PTSD with very few traumatic events for 
individuals with the Met/Met genotype without an effect on lifetime PTSD prevalence.  
Traumatic load was also noted as a risk factor for the frequency of lifetime PTSD for 
genotypes Val/Met and Val/Val.  When more than 15 traumatic events occurred, 
56 
 
 
differences in prevalence rates between genotypes did not occur.  Limitations of the study 
included: the small sample size for Met/Met genotypes and lack of identifying other 
comorbid Axis I disorders (Kolassa, Kolassa, et al., 2010).  Genetic sleep research is 
beyond the scope of this dissertation however, the COMT (Val 158Met polymorphism) 
has been studied in a healthy population by Goel et al. (2011) related to chronic partial 
sleep deprivation (PSD).  Goel et al. (2011) suggest the COMT Val158Met region may 
predict sleep patterns in healthy individuals as well as shed light on sleep related 
difficulties in other psychiatric conditions. 
The nongenetic relationship between sleep and PTSD is well established.  Klein et 
al. (2003) studied 102 participants (26 with PTSD and 76 trauma exposed without PTSD) 
and 19 patients for one year who were having elective orthopedic surgery.  Participants 
were followed at 1 week, 3 months, and 12 months.  PTSD individuals reported more 
insomnia for week 1 compared to victims of trauma without PTSD or the comparison 
group.  At 1 month, both insomnia and excessive daytime sleepiness (EDS) were 
significant in the PTSD group compared to the other groups.  When the three sleep 
variables (duration, efficiency, and restfulness) were further examined, PTSD participants 
had a shorter duration compared to the other groups.  This was noted at the three month 
interval but did not continue to the 12 month time period.  At 12 months, the PTSD and 
non PTSD groups slept longer than the control group.  No other correlations were noted.  
Klein et al. conducted a follow up study one year later with eight PTSD participants and 
six non-PTSD participants and found no significant differences between participant 
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groups.  The authors suggest sleep misperception may be the primary complaint for 
PTSD participants.                      
Lewis et al (2009) studied 541 Australian male Vietnam combat veterans with and 
without PTSD.  Veterans with PTSD had statistically significant mean scores on sleep 
quality, sleep latency, sleep duration, sleep disturbances, sleep medication, daytime 
dysfunction, and a global sleep score; only sleep efficiency was not found to have a 
statistically significant difference.  Lewis et al. indicated PTSD veterans had the highest 
scores compared to other community samples and suggested that sleep problems in 
veterans may be the result of changes that have to be made in sleep schedules to 
accommodate the demands of the military or sleep problems, such as nightmares that lead 
to changes in sleep patterns.   
Germain, Hall, Shear, Nofzinger, and Buysse (2006) studied effects sizes in 
PTSD individuals (n = 10) and a group of healthy controls (n = 5).  Medium effect sizes 
were noted between PTSD cases that had more sleep disturbances and stress symptoms.  
Variables with the largest effects (either medium to large effect sizes) between the PTSD 
and the control group were for two specific sleep disturbances: apnea-hypopnea index 
(AHI) and periodic limb movements with arousal (PLMA); large effect sizes were noted 
for the percentage of Stage 3 and 4 sleep and for wake time after sleep onset (WASO).  
On visually scored variables, effects were noted; PTSD cases had longer sleep latency 
and shorter sleep duration (Germain et al., 2006).  REM latency had a large effect size 
compared to time spent in REM sleep and REM Count. A small effect size was noted for 
controls in the percentage of time spent in Stage 3, Stage 4, and WASO.   
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van Liempt et al. (2011) studied obstructive sleep apnea (OSA) in 20 veterans 
with PTSD, 24 veterans without PTSD (trauma controls), and 17 health controls (HC) 
matched to PTSD trauma veterans on age, year, and region of deployment.  There were 
15 apnea hypopnea indices (AHI) in the PTSD group (10%) compared to 13% in trauma 
controls and 12% in health controls, though no significant results were found.  There 
were greater than 10 AHI per hour noted in 29% of PTSD participants, 21% of trauma 
controls, and 29% of healthy controls, though no significant results were noted.  
Participants with AHI scores of greater than10 also had higher PTSD CAP scores 
compared to those without OSA.  CAPS and AHI were significant for PTSD participants; 
subscales that correlated to CAP scores for PTSD found a relationship with the D 
subscale related to hyper arousal symptoms (van Liempt et al., 2011). 
A meta-analysis of 20 studies representing various types of trauma (i.e., civilian 
trauma, combat trauma, accident, war related trauma, or weather related trauma) was 
completed by Kobayashi et al. (2007).  They found that PTSD individuals, regardless of 
gender, had more difficulty with Stage 1 sleep, REM density (REMD), and slow wave 
sleep (SWS).  Male PTSD participants specifically had shorter total sleep time (TST), 
Stage 2, longer sleep onset latency (SOL), and REMD.  Kobayashi et al. indicated in the 
male group, participants were members of the military.  Age, sex, depression, and 
substance use moderated the effects of sleep on PTSD; Kobayashi et al. suggested that 
these moderator variables may explain some of the conflicting results obtained from 
previous studies.  Younger individuals with PTSD did not have more sleep difficulties.  
Kobayashi et al. reported the time since the traumatic experience may have impacted the 
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findings on age and its effect on sleep.  Type of trauma (military vs. nonmilitary) may be 
associated with greater sleep difficulties (Kobayashi et al., 2007).  Substance use 
moderated PTSD on REM, REM latency with REMD having the most significant impact.  
Kobayashi et al. suggested that this may be related to the hyper arousal symptoms of 
PTSD however it is unclear if substance usage occurs before hyper arousal symptoms 
develop or if substances are used in response to hyper arousal symptoms.   
Gellis et al. (2010) examined 201 veterans with PTSD from the Iraq and 
Afghanistan Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF).  Sleep 
difficulties of the veterans included nightmares and difficulties initiating and maintaining 
sleep (DIMS).  Of the 201 participants, 64 participants suffered from severe nightmares, 
38 experienced moderate nightmares, and 99 reported little or no nightmares.  Severe 
DIMS was reported by 122 participants:  33 reported moderate DIMS and 46 had no 
DIMS or little difficulty with DIMS.  An association was found between nightmares and 
DIMS.  Additionally, African Americans reported greater DIMS compared to 
Caucasians.  Odds ratios found severe DIMS was associated with nonsleep PTSD 
severity (OR = 1.14) and moderate DIMS (OR = 1.06).  Nonsleep related PTSD 
symptoms had higher OR for severe (OR = 1.11) and moderate nightmares (OR = 1.06).    
van Liempt et al. (2011) examined nightmares and obstructive sleep apnea (OSA); no 
significant results were found related to nightmares, obstructive sleep apnea (OSA), and 
CAP subscales.   
Langston et al. (2010) studied 47 children and adolescents that suffered from 
nightmares.  The sample consisted of children and adolescents that experienced 
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nightmares prior to a traumatic experience (28% reported idiopathic nightmares), 
nightmares that began following a traumatic experience (23%), or no nightmares (49%).  
Individuals exposed to a traumatic experience reported weekly nightmares (Langston et 
al., 2010).  Langston et al. found participants with PTSD related nightmares compared to 
those with no nightmares had more difficulty with time to get to sleep, sad upon waking, 
global sleep quality, depression, and PTSD. They indicated it is unclear what may be the 
reason for these differences and suggest the traumatic event may play a role in the 
differences noted.   
Both post trauma nightmares and the idiopathic nightmare group reported a fear 
of sleep and poor sleep when compared to those without nightmares (Langston et al., 
2012).  Both groups also reported being "scared of dying, scared of being hurt, felt very 
scared, and felt unable to stop what was happening” (Langston et al., 2010, p. 351).   
Compared to idiopathic nightmares, the post trauma nightmare group had more panic 
symptoms when they woke up (Langston et al., 2010).  The authors evaluated if type of 
trauma impacted nightmares and found no relationship with the exception of sexual 
abuse.  When the traumatic experience was sexual abuse more post trauma nightmares 
were noted, 55% compared with 9% (Langston et al., 2010).    
Limitations of studies related to PTSD and sleep have included small sample 
sizes, low power, and results that cannot be generalized beyond study participants.  
Results may be limited by concerns with measurement tools.  For example, the DIMS 
was identified through a single assessment which may not adequately assess insomnia; 
more sensitive measures may be used to detect OSA; and the self-report nature of the 
61 
 
 
measurement tools may limit the interpretations as structured interviews did not verify 
self-reports; child measurement tools were modified from adult tools as child tools were 
not available; the measurement tool may not accurately collect sleep dimensions; the 
subjective self-report of sleep was not collected on the days when objective sleep data 
were collected.   
The type of data used (self-report) may present problems.  The study design may 
limit results.  In one study only two sample groups were included in the study design, 
which limited additional evaluation of interaction effects.  The time since the trauma was 
not considered so there may be additional sleep difficulties immediately following trauma 
that are not considered.  Other variables such as depression, traumatic brain injury, and 
alcohol dependence may impact sleep difficulties independently; comorbid conditions 
which may be related to sleep problems, or there may be other sleep variables related to 
sleep and PTSD that were not considered; other potential moderators may be present such 
as hospitalization, location or type of sleep monitoring, comorbid sleep disorders, trauma 
related nightmares, and medication use.  Diagnosis may also limit results.  In one study,  
the PTSD diagnosis was confirmed at 1 year however, other participants may have met 
the diagnosis earlier but were not included in the PTSD sample (Gellis et al., 2010; Klein 
et al., 2003; Kobayashi et al., 2007; Langston et al., 2010; van Liempt et al., 2011).    
Walker's (2009) hypothesis suggests sleep disorders associated with emotional 
disorders may not be a symptom of the disorder but may be the mechanism for the 
development of the emotional issue.  As noted by Langston et al. (2010) children and 
adolescents that experienced nightmares following a traumatic event experienced more 
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distress than individuals without nightmares, particularly among individuals that had 
experienced sexual abuse.  Of the different types of traumatic experiences, only sexual 
abuse was found to be associated with nightmares in Langston et al.'s study. Interestingly, 
individuals already experiencing nightmares and then having a traumatic experience did 
not have greater development of PTSD symptoms and did not have greater distress 
somewhat supporting Walker's hypothesis that sleep problems associated with emotional 
disorders may be the conduit for the development of the emotional issue (Langston et al., 
2010; Walker, 2009).          
Walker and van der Helm (2009) suggest that the adrenergic and cholinergic 
systems as well as the cortex, hippocampus, and amygdala are involved in sleep and 
memory consolidation.  Although sleep neurobiology is beyond the scope of this 
dissertation, many of these same systems or areas of the brain have also been associated 
with PTSD through candidate gene or genetic allele studies and may increase an 
individual’s risk for the development of PTSD.  Pathways studied related to PTSD 
include glucocorticoid, dopamine, glutameric, and serotonin systems.  Other candidate 
genes or genetic alleles play a role in the hypothalamic pituitary adrenal (HPA) axis and 
are involved in the stress response or in fear processing.    
Genome-Wide Association Studies (GWAS) 
Logue et al. (2012) examined 295 white, non-Hispanic veterans (men and 
women) with PTSD and 196 of their partners who acted as controls.  Replication analysis 
was done with an African American population from a veteran cohort (PTSD cases = 43 
and controls = 41) and the Detroit Neighborhood Health Study (cases = 100 and controls 
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= 421).  Logue et al. found SNP rs8042149, in the retinoid-related orphan receptor alpha 
gene (RORα) reached genome wide significance and was associated with PTSD.  SNP 
rs8042149 was analyzed to determine if genotype, probability of PTSD, and total number 
of traumatic events (NTE) were associated.  Logue et al. found that “the probability of 
PTSD diagnosis by genotype indicated subjects with low levels of trauma exposure and a 
high risk (GG) genotype had a similar likelihood of developing PTSD as those from the 
high exposure but low risk (AA) genotype” (p. 3).  The number of traumatic events was 
associated with risk for PTSD and gene rs8042149 was also significant.  In the African 
American population, rs8042149 did not reach significance however rs1171588 remained 
significant in this population even after adjustment for multiple testing.  In the DNHS 
sample, SNP rs16942660 was associated with lifetime PTSD.  Logue et al. indicated that 
different SNPs in RORα may be associated with different ancestries and a function of 
different linkage disequilibrium patterns.  A limitation noted by Logue et al. was the 
possibility of false associations due to chance and the small sample size.    
Xie et al. (2013) conducted a GWAS using a sample that consisted of 1,633 
(including 300 PTSD cases) European Americans (EA) and 2,766 (including 444) 
African Americans (AA); EAs and AAs were recruited from genetic studies on alcohol, 
cocaine, and opioid dependence recruited from five U.S. sites.  The SSADDA was the 
tool used in this study.  One SNP rs406001 on chromosome 7p12 exceeded the threshold 
for genome wide significance.  Cordon-Bleu [COBL] is the gene closest to this region.  A 
sub analysis focusing on a GWAS of PTSD subjects exposed to trauma identified SNP 
rs406001 on chromosome 7p12 for EAs was the most significant, however none of the 
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SNPS reached genome wide significance.  Xie et al. completed replication analyses and 
found in the EA population SNP, rs6812849; in the Tolliod-Like 1 gene [TLL1] was 
successfully replicated.  Interestingly, Xie et al. suggested that trauma exposure is less of 
a contributing factor to the development of PTSD; they indicated the genetic region 
identified in their study, TLL1, may be a better predictor of PTSD than trauma exposure 
and indicated this region is a “new susceptibility gene” (p. 656).   Xie et al. did not find 
any genome wide associations among the AA populations studied.  Nor did they find any 
associations that were consistent with other genome wide association studies on PTSD.  
Limitations noted by Xie et al. included their study population was from a substance 
dependence study and therefore results may not be generalized to other PTSD 
populations; additionally, sample sizes were small in this study and specific to European 
Americans.       
Guffanti et al. (2013) conducted a genome wide association study that focused on 
PTSD, specifically in women.  Guffanti et al. suggested that gender played a greater role 
in the genetics associated with PTSD.  They focused their study on African American 
women from the Detroit Neighborhood Health Study and attempted to replicate their 
study using a cohort of European American women from the Nurses Health Study II 
(NHS II).  SNP rs10170218 in the ACO68718.1 region reached genome wide 
significance in the DNHS sample and was tested for evidence of association in the NHS 
sample.   A sub analysis was also done to account for potential differences related to 
racial differences using a dominant and recessive model (Guffanti et al., 2013).  SNP 
rs10170218 had the strongest signal.  The replication analysis found the same SNP with 
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the minor allele “C” frequency to be 0.27 in the NHS II population compared to 0.22 in 
the DNHS.  Guffanti et al. describe RNA gene ACO68718.1 as lincRNA that has 
“transposable elements (TE)” which are “discrete pieces of DNA that can move within 
genomes, inserting themselves into new genomic sites and generating interspersed 
repeats of the original TEs” (p. 5).  SNP rs10170218 maps to Intron 3-4, 236 kb upstream 
from exon 4 overlapping with class LTR8B; little is known about the functions associated 
with this genetic region.  Limitations noted by Guffanti et al. included: the use of 
telephonic interviews to determine PTSD that may have biased their results and the study 
was designed to only find strong genetic effects.    
Solovieff et al.’s (2014) study different somewhat from the other three GWAS.  
They used results from the Psychiatric Genome Wide Association Studies Consortium 
(PGC) to test 3,742 SNPs across 300 genes in trauma exposed European American 
women (845 PTSD cases and 1,693 controls).  Solovieff et al. tested an association with 
the SNPs and two PTSD measures: severity score and diagnosis.  PTSD diagnosis was 
found to be associated with SNP rs363276 (OR = 1.4, p = 2.1x10
-5
) in SLC18A2.  Nine 
SNPs in this same region, including the SNP with an association was analyzed in a 
haplotype analysis.  A risk haplotype (CGGCGGAAG, p = 0.0046) was significant and 
then replicated in an independent cohort of trauma exposed African Americans (p = 
0.049).  The SLC18A2 has been associated with other psychiatric disorders including 
major depression but had not been previously identified for PTSD.  Solovieff et al. found 
eight genes (APOE, BDNF, COMT, FKBP5, HTR2A, SLC6A3, SLC6A4, and TPH2), 
previously identified in the literature associated with either PTSD diagnosis or severity; 
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none of the results remained significant after adjusting for multiple testing.  They also 
completed separate analyses on each of the regions identified in the other three published 
GWAS.  They replicated only lincRNA ACO68718.1 from Guffanti et al. (2013).  
Limitations noted included: phenotypic data were identified by telephone allowing for the 
possibility of misclassification of PTSD and the study had low power to detect weak 
effects (Solovieff et al., 2014).       
The GWA studies published have reported on different areas of the genome.  
Limitations to the studies may be due to sample size; however, sample sizes have been 
consistent with other GWAS on PTSD (Guffanti et al., 2013; Logue et al., 2012; Xie et 
al., 2013).  Walker and van der Helm (2009) indicate memory and sleep may be an 
appropriate theoretical framework to work from when examining PTSD and other 
psychiatric issues that have sleep problems as part of their presentation.  Logue et al. 
(2012) found that SNP rs8042149, in the retinoid-related orphan receptor alpha gene 
(RORα) reached genome wide significance and was associated with PTSD.  The RORα 
gene is thought to be a gene involved in circadian rhythm functioning (Akashi & Takumi, 
2005).  The RORα gene was found to be important in regulating Bmal1 transcription 
factor in mice (Akashi & Takumi, 2005).  When the RORα did not function properly in 
promoting Bmal1, the circadian rhythm did not function properly; the RORα was 
considered a “component of the core circadian clock”… and “acts as to promote Bmal1 
transcription, thereby maintaining a robust circadian rhythm” (Akashi & Takumi, 2005, 
p. 441).  The RORα gene may be involved in chronic inflammatory processes such as 
heart disease or arthritis (Delerive et al., 2001); Boscarino (2008) found individuals with 
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higher PTSD scores had a 20% increased risk of mortality from heart disease.  Logue et 
al. suggested risk for PTSD from the RORα gene may “confer…a trait negative 
emotionality…conceptualized as a primary temperamental risk factor” (p. 5).  I suggest 
the RORα gene’s impairment leads to the disruption of the normal sleep cycle initiating a 
cascading effect that impacts memory consolidation and processing of emotional content.   
Summary and Conclusions 
This literature review provided a comprehensive review of the literature on PTSD 
including genetic alleles and their relationship to PTSD.  The review identified genetic 
alleles that conferred risk for PTSD, those with mixed results, and genetic alleles that 
may confer protective factors.  Genetic alleles associated with specific PTSD symptoms 
were reviewed.  The literature associated with sleep, a symptom associated with PTSD, 
and PTSD has been well established and was reviewed to establish the importance of the 
theoretical hypothesis / framework (Walker & van der Helm, 2009).  Recent GWA 
studies were also reviewed.  Chapter 3 reviews the study design, methodology, and 
statistical analysis for the study. 
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Chapter 3: Research Method 
Introduction 
This dissertation study involved the use of a human genome epidemiology 
approach to focus on discovering the possible genetic risk factors associated with 
posttraumatic stress disorder using a case control study design and a genome-wide 
association study method (GWAS) to compare the genome of individuals with PTSD to 
that of controls. Any genetic allele reaching genome-wide significance was further 
analyzed in a multi-step process to determine whether there is an association between the 
allele and the main symptoms of PTSD and then the sub symptom of sleep.  Prior 
research has focused on individual genetic alleles in PTSD rather than the whole genome.  
The published genome-wide association studies (GWAS) on PTSD have identified new 
areas of the genome not previously discovered (Guffanti et al., 2013; Logue et al., 2012; 
Solovieff et al., 2014; Xie et al., 2013).  Only one study (Solovieff et al., 2014) replicated 
the results from other GWAS.  However, none of these studies have addressed the 
symptoms of PTSD, specifically the symptom of sleep, in the context of the genome.       
Chapter 3 contains an outline of the design, methodology, and statistical analysis 
that were used in this study.  The chapter begins with a review of the research design and 
rationale, followed by information on both the independent and dependent variables.  The 
population is reviewed along with the sampling procedure.  Procedures for recruitment 
are reviewed.  This study used archival data (both genetic and survey data); information 
on the use of archival data is provided.  The instrumentation and the operationalization of 
the instrument are reviewed.  The chapter continues with a review of threats to validity 
69 
 
 
and the data analysis plan. The reader is reminded of the research questions under study.  
Ethical procedures are reviewed.  The chapter concludes with implications for the study.   
Research Design and Rationale 
The gap in the literature at the time of the start of this dissertation suggested that a 
genome-wide association approach was needed to study the possible complex pathway(s) 
for PTSD development (Cornelius et al., 2010; Feodorova & Sarafian, 2012; Norrholm & 
Ressler, 2009).  Four GWAS studies have been completed; however, none of these 
studies have examined PTSD symptoms or specifically the sleep symptom of PTSD and 
the human genome (Guffanti et al., 2013; Logue et al., 2012; Solovieff et al., 2014; Xie et 
al., 2013).   The genome wide association method was chosen for the study design, as the 
literature suggested that PTSD had a number of potential genetic risk factors.  Whole 
genome association studies (WGAS) allow the researcher to examine the entire genome, 
limiting errors related to missed associations that can occur when studying specific 
candidate genes, and is effective for studying complex diseases with multiple possible 
contributory genes (National Library of Medicine, 2011).   
Independent and Dependent Variables 
The independent variable was PTSD status (i.e., individuals [cases] with PTSD 
vs. controls [individuals without PTSD]).  The dependent variables were the main 
symptoms of PTSD with specific focus and analysis on the variable of sleep, a sub 
symptom of the hyper arousal symptoms.  Following the initial analysis, any genetic 
allele that reached genome-wide significance moved to a second phase of analysis to 
discover whether a correlation existed between the genetic allele and the main 
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symptom(s) of PTSD.  The final step in the analysis was to analyze any genetic allele 
reaching significance with the sleep variable. 
Covariates 
Covariates identified in the literature have included age, sex, race, socioeconomic 
status, number of traumas, smoking, lifetime depression, and other Axis I disorders 
(Change et al., 2012; Shea, Vujanovic, Mansfield, Sevin, & Liu, 2010; Udden et al., 
2011).  Other covariates include BMI, gender, use of anxiolytics, antidepressants, type of 
trauma, age at which trauma occurred, intensity of trauma, education, rural/urban, other 
co-occurring disorders such as major depressive disorder, drug dependence, substance 
abuse, Axis 2 disorders, and self-esteem (Al-Turkait & Ohaeri, 2008; Babson et al., 2011; 
Frans et al., 2005; Krakow, Germain, et al., 2001; Krakow, Hollifield, et al., 2001; Udden 
et al., 2011).  Nishi et al. (2012) identified that a covariate of watching television 
coverage of the Great East Japan earthquake of 2001 for more than 4 hours predicted 
PTSD symptoms among rescue workers.   
Mediator Variables 
Carlozzi, Reese-Melancon, and Thomas (2011) suggested that depression may be 
a mediator variable in individuals with PTSD and memory complaints.  There were no 
differences noted between groups for objective memory; however, group differences 
were noted for subjective memory, with individuals with PTSD reporting more subjective 
memory complaints.  When depression was included as a covariate, subjective memory 
differences did not occur (Carlozzi et al., 2011). 
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Moderator Variables 
A database from the NCBI that contained genomic data on individuals with PTSD was 
requested.  The database contained data on age, race, ethnicity, gender, sedative 
dependence, tobacco dependence, stimulant dependence, and substance abuse.  These 
variables were the covariates for the second phase of analysis.  The study variables in the 
database are consistent with what has already been identified in the literature under 
covariates.  Other disorders, particularly substance use disorders, are often co morbid 
with PTSD.  Because the original study, phs000425.v1.p1, “Alcohol Dependence GWAS 
in European and African Americans,” was collected as part of a substance abuse genome 
set, substance abuse was included as a covariate in this dissertation.  In a study by Xie et 
al. (2010) alcohol dependence had an interactive effect between childhood maltreatment 
and the FKBP5 polymorphism on increased PTSD risk.   
Population 
A genome-wide database with de-identified data were requested from the 
National Library of Medicine’s National Center for Biotechnology Information (NCBI).  
The dbGaP database contained a GWAS dataset that was collected as part of a study on 
alcohol dependence in European and African Americans (Gelertner & Krazler, 2010); 
PTSD was included as one of the study variables collected as part of the dataset.  The 
target population was composed of individuals identified with posttraumatic stress 
disorder (PTSD) whose genomic data were collected as part of a larger genome wide 
association study on alcohol dependence by dbGAP from the National Center for 
Biotechnology Information (NCBI).  PTSD status was determined from the SSADDA 
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tool.  The study collected genomic data from 2,909 individuals: 1,889 African 
Americans, 1,020 European Americans, and 491 control subjects.  Approximately 500 
individuals with PTSD were identified in the original study.  The following statement is 
provided to acknowledge the original study: 
Funding support for the [CIDR-Gelernter Study] was provided through the Center 
for Inherited Disease Research (CIDR) and the Genetics of Alcohol Dependence 
in American Populations (CIDR-Gelernter Study)]. [CIDR-Gelernter Study] is a 
genome-wide association study funded as part of the [Genetics of Alcohol 
Dependence in American Populations]. Assistance with phenotype harmonization 
and genotype cleaning, as well as with general study coordination, was provided 
by the [Genetics of Alcohol Dependence in American Populations].  Assistance 
with data cleaning was provided by the National Center for Biotechnology 
Information.  Support for collection of datasets and samples were provided by the 
Genetics of Alcohol Dependence in American Populations (R01 AA011330). 
Funding support for genotyping, which was performed at the Johns Hopkins 
University Center for Inherited Disease Research, was provided by the NIH GEI 
(U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, and 
the NIH contract ’High throughput genotyping for studying the genetic 
contributions to human disease’ (HHSN268200782096C). The datasets used for 
the analyses described in this manuscript were obtained from dbGaP at 
http://www.NCBI.nlm.nih.gov/sites/entrez?Db=gap through dbGaP accession 
number [phs000425]. (Data Use Certificate Agreement, 2010, pp. 4-5) 
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Sampling and Sampling Procedures 
Using the population of 500 individuals with PTSD with a 95% confidence level 
and a confidence interval of 4, the sample size required for cases is 273.  A 99% 
confidence interval requires a sample size of 338.  Data were collected on 491 controls.  
Using a 95% confidence level and a confidence interval of 4, the sample size required for 
the control population is 270.  A p value of α = 95% is consistent with the literature for 
GWA studies (Qu, Tien, & Polychronakos, 2010).  An online sample size calculator was 
used from (http://www.surveysystem.com/sscalc.htm) to calculate the sample size noted 
below for both cases and controls.   
Table 1 
Determining Sample Size—Cases 
Confidence 
Level: 
99% 
 
Confidence 
Interval: 
4 
 
Population: 
500 
 
Sample size 
needed: 
338 
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Table 2 
Find Confidence Interval—Cases 
Confidence Level: 99% 
Sample Size: 338 
Population: 500 
Percentage: 50 
Confidence Interval: 4 
 
Table 3 
Determining Sample Size—Controls 
Confidence 
Level:  99% 
Confidence 
Interval: 
4 
Population: 491 
Sample size 
needed: 
334 
 
Table 4 
Find Confidence Interval—Controls 
Confidence Level:  99% 
Sample Size: 334 
Population: 491 
Percentage: 50 
Confidence Interval: 4 
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A request was made for the database of the 500 individuals with PTSD and the 
491 controls along with a request for individual, de-identifiable data on both cases and 
controls.  The entire population was used to complete this study.  The sample size in 
other GWA studies have ranged from 94-444 PTSD cases (Guffanti et al., 2013; Logue et 
al., 2012; Xie et al., 2013).  Logue et al. (2012) had 295 cases and 196 controls; Xie et al. 
(2013) had 300 and 444 PTSD cases respectively; and Guffanti et al. (2013) had 94 
PTSD cases.    The study design has adequate power using the entire PTSD population 
and controls.  I acknowledge there was no PTSD only population without substance 
abuse.  Substance abuse was evaluated as a covariate and this limitation was noted in the 
limitations section of the study.  Although this is a limitation of the dissertation, this 
population group, use of PTSD cases collected as part of a substance abuse study was 
consistent with other published literature (Xie et al., 2013).  
Use of Archival Data 
A case control genome wide association study was conducted by the National 
Center for Biotechnology Information (Gelertner & Krazler, 2010).  The original study 
phs000425.v1.p1 titled “Alcohol Dependence GWAS in European and African 
Americans” collected genomic data on alcohol dependence (NCBI) using the Semi 
Structured Assessment for Drug Dependence and Alcoholism (SSADDA) questionnaire; 
which assessed for alcohol and other psychiatric disorders including posttraumatic stress 
disorder (Gelertner & Krazler, 2010).  The study collected genomic data from a total of 
2,909 individuals, 1,889 African Americans, 1,020 European Americans, and 491 control 
subjects, which were collected over three studies that focused on genomic data associated 
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with alcohol, cocaine, and opioid dependence.  Affected sib pairs were collected during 
the studies when available.  Inclusion criteria in the original study were individuals with a 
DSM-IV diagnosis of alcohol dependence.  Excluded were individuals with diagnoses of 
schizophrenia, bipolar affective disorder, other major psychotic illnesses, or individuals 
with gross cognitive impairment (Gelertner & Krazler, 2010).  A total of 24 variables 
related to alcohol, phobias, or other psychiatric disorders were collected as part of this 
study including individuals with PTSD.  Additional variables specific to alcohol related 
issues (i.e., tolerance, withdrawal, and sedative use) were collected.  Demographic data 
collected included gender, age, and race (Gelertner & Krazler, 2010).   Whole genome 
typing was done by Illumina using the HumanOmni1_Quad_v1-0_B platform.   Genomic 
data were collected on approximately 500 individuals with PTSD as part of the original 
study (Gelertner & Krazler, 2010).  Information about the dataset indicated the database 
should be used in connection with substance abuse research.  Only a subset of the 
database was requested; the data associated with the PTSD variable.  A request was made 
to the National Center for Biotechnology Information for access to only the PTSD section 
of the database including the individual level dataset that included the responses to the 
SSADDA questionnaire.  To obtain access to the controlled individual-level data, the 
Principle Investigator (PI) and the Signing Official (SO), which was required to be a 
representative from the institution, someone with institutional authority, typically this 
would be a Dean of a program had to cosign the request for data access (eRA Commons, 
2013).  The information provided on the SO indicated the SO could delegate this function 
to another person; I requested Dr. Shen, my Chair, be delegated this function (eRA 
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Commons, 2013).  The SO is responsible for ensuring the safety of the genomic data, 
which is consistent with Dr. Shen’s and my role was in the course of this dissertation.  
The PI directed the research project (eRA Commons, 2013).  The request for the database 
was made to the NIH Data Access Committee at the appropriate NIH Institute or Center, 
in this case, the Joint Addiction, Aging, and Mental Health DAC.  Please note both the PI 
and the SO were required to have an eRA commons account and co-sign a request for 
data access.  These are the same accounts used to apply for grants.  In the eRA commons 
account when there is a first request for data, a new data request must be filled out by the 
PI.  Form SF 424 (R&R) must be completed.  This form was completed and submitted to 
Dr. Shen and the IRB.   IRB approval was required and to be submitted with SF 424.  
Basic information on the research project was also required that included: the  title of the 
research, the type of research, a statement of no more than 2,000 characters describing 
the research, a non-technical summary of no more than 1,100 characters, and information 
on the SO and PI.   
I acknowledge that requesting the data constituted an agreement to the terms of 
use specified in the “Data Use Certification” (DUC) documents provided on the website.  
The DUC statements outline policies and procedures for using the data, such as limiting 
use to the project described in the Data Access Request form; not distributing the data 
beyond those permitted to handle it; not attempting to identify or contact study 
participants from whom phenotype data and DNA were collected; awareness of the 
specified principles regarding intellectual property; adhering to policies on the timeframe 
for publications stemming from the data; and other provisions designed to protect the 
78 
 
 
confidentiality of study participants and foster scientific advance (Data Use Certificate 
Agreement, 2010).  To ensure applications moved through the submission and review 
process in a timely way, the SO and PI received various emails providing updates on the 
status of the request or any required actions. The data access request was then reviewed 
by the appropriate Data Access Committee(s) at NIH.  
Instrumentation and Operationalizing Constructs 
Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) 
The original study, phs000425.v1.p1 titled “Alcohol Dependence GWAS in 
European and African Americans” collected data on PTSD using the Semi-Structured 
Assessment for Drug Dependence and Alcoholism (SSADDA) (Gelertner & Krazler, 
2010).  The SSADDA is a tool developed to study genetic association studies involving 
cocaine and opioid dependence (Pierucci-Lagha et al., 2005).  The SSADDA tool was 
originally developed from the Semi-Structured Assessment for the Genetics of 
Alcoholism (SSAGA); a free copy of the tool is available at 
http://genetics.bumc.bu.edu/ssadda/ (Boston University, n.d.).  “The SSADDA provides 
extensive coverage of the physical, psychological, social, and psychiatric manifestations 
of cocaine and opioid abuse and dependence in addition to a number of related Axis I and 
Axis II disorders” (Samet et al., 2007, p. 28).  The PTSD section of the SSADDA 
collected data on 12 different types of traumatic experiences that included: direct combat 
in a war; seriously physically attacked or assaulted; physically abused as a child; 
seriously neglected as a child; raped; sexually molested or assaulted; threatened with a 
weapon; held captive or kidnapped; witnessed someone being badly injured or killed; 
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involved in a flood, fire, or other natural disaster; involved in a life-threatening accident; 
suffered a great shock because one of these events happened to someone close to you; 
and other (Xie et al., 2009).   There are 24 questions with various sub questions that 
focused on PTSD symptoms.  A computerized version of the tool allowed for direct entry 
of responses by participants as well as a direct upload of data to a database (Boston 
University, n.d.).   
Pierucci–Lagha et al. (2005) examined inter rater reliability and test retest 
reliability for the SSADDA using 293 participants in two sub studies.  For the PTSD 
section of the tool, they found inter-rater reliability rates to be fair (k = 0.59, 95% CI 
0.40-0.77; Y = 0.73) and test retest reliability to be k = 0.76 (95% CI 0.53-0.99), Y = 0.88.  
PTSD was the only diagnosis whose prevalence rates increased between the test and 
retest period (p = 0.041; Pierucci-Lagha et al., 2005).  The SSADDA tool has been used 
in studies related to genes and PTSD; Xie et al. (2009) studied interactive effects of 
PTSD, childhood adversity, adult trauma, gene (5 HTTLPR region), and gene 
environment interactions.   Douglas et al. (2010) used the SSADDA to evaluate adverse 
childhood experiences (ACE) as risk factors for substance abuse.  Ford et al. (2009) used 
the SSADDA to evaluate co morbid psychiatric and substance disorders treatment 
utilization in the context of several groups diagnosed with cocaine dependence.  
Thavichachart et al. (2009) used the SSADDA to identify the presence of chronic PTSD 
following the December 2004 tsunami off the Andaman Coast in Thailand.  The 
SSADDA has also been used to study attention deficit hyperactivity disorder and 
substance abuse disorders (Arias et al., 2008); has been used in genome-wide association 
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studies on substance abuse disorders (Gelernter et al., 2006) and a genome wide 
association study on PTSD (Xie et al., 2013).  
Threats to Validity 
External Validity 
Testing reactivity was not a factor as the study design was not a pretest posttest 
study design (Southern Utah University [SUU], n.d.).  Interaction effects were not a 
factor as neither the study population nor the experimental variables were so unique or 
specialized that results cannot be generalized (SUU, n.d.).  Participants in the original 
study were both Caucasian and African American; Hardy Weinberg equilibrium 
determined that the groups were comparable.  The sample included the entire sample of 
PTSD cases and controls and had adequate power; I suggest the results are applicable 
only to the population under study at this time.  Reactive effects were minimized as 
genomic data is not subject to the same biases as survey data.  The use of the SSADDA 
data did not eliminate reactive effects as the original study design was not a naturalistic 
observation (SUU, n.d.).  Multiple treatment interference was not a concern as the study 
was not examining the effect of any treatment (SUU, n.d.).         
Internal Validity 
History was not considered a threat to internal validity for genomic data; in terms 
of the data collection from the questionnaires, history was not be a concern as multiple 
testing did not occur in the study design (SUU, n.d.).  The study was not subject to 
maturation (testing was not occurring over a long period of time) (SUU, n.d.).  Testing 
(i.e., the Hawthorne effect) was a concern as participants were aware they were 
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participating in a study (SUU, n.d.).  Instrumentation was not a concern for this study as 
specific instruments were not being used (SUU, n.d.).  Statistical regression was not a 
concern as this was not a repeated measures design (SUU, n.d.).  Experimental mortality 
was not a concern as all the data from the original study have been collected.  Selection 
maturation was not a concern with the population under study (SUU, n.d.).    
Threats to Construct or Statistical Conclusion Validity 
Sources of bias in genetic epidemiology include selection bias, information bias, 
and confounding (Garcia-Closas, Wacholder, Caporaso, & Rothman, 2004).  The original 
study included genomic data from participants during three different studies.   The 
potential for information bias related to misclassification or measurement error from the 
original study phs000425.v1.p1, “Alcohol Dependence GWAS in European and African 
Americans” (i.e., “biological sample collection, processing and storage, sample labeling, 
DNA extraction and storage, laboratory assays, data coding, entry and analysis”) was 
addressed by ensuring the two groups were in Hardy Weinberg equilibrium (Garcia-
Closas et al., 2004, p. 131; Gelertner & Krazler, 2010).  Potential confounders identified 
in the literature, race, ethnicity, gender, age, sedative dependence, stimulant dependence, 
tobacco dependence and substance abuse, were evaluated to determine if they should be 
included as covariates for the second phase of analysis.      
Operationalization 
The SSADDA tool (Pierucci-Lagha et al., 2005) uses a number of questions that 
identify symptoms (re-experiencing, avoidance/numbing, hyper arousal, and sleep) 
associated with PTSD.  Participants responded with a “yes” or “no” when answering the 
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questions.  These questions operationalized PTSD symptoms.  Examples of some of the 
questions are noted below:      
Re-Experiencing/Intrusion 
O2 Did memories, visions, thoughts, or feelings about (EVENT) often keep 
coming to your mind even though you didn’t want them to? 
O4 Did you ever suddenly act or feel as if the (EVENT) was happening again?  
This may include flashbacks, or hallucinations, even if they occur when you 
are just waking up? 
 Avoidance/Numbing 
O8 Did you ever try to avoid thinking about or having feelings about (EVENT) 
and find that you couldn’t? 
O9 Did you ever avoid activities, places, or people that reminded you of 
(EVENT)? 
O12 During that period of time, did you feel more cut off, distant, or separated 
from people than before the (EVENT) happened?  
O13 Were there times when you believed you had lost the ability to experience 
emotions that you had before (EVENT) happened?   For example, did you feel 
you couldn’t have loving feelings or anything like that?  
O14 Were there times when you felt that there was no point in planning for the 
future-that you might not have a rewarding career; a happy family; or a long, 
good life?  
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Hyper Arousal 
06 Did things that remind you of the (EVENT) make you sweat, tense up, 
breathe hard, tremble or respond in some other physical way? 
O19 Were there times when unexpected noise, movement, or touch startled you 
more than before (EVENT)? 
O20 Were you more watchful or extremely aware of things around you? For 
example, were you more aware of certain sounds, smells, or sights?   
The SSADDA had questions specific to sleep and memory.   
Sleep 
O3 Did you have unpleasant dreams again and again about (EVENT)? 
O16 Did you have more trouble falling asleep or staying asleep than before 
(EVENT)? 
Memory 
O10 Did you find that you sometimes could not remember important things about 
(EVENT)? 
The SSADDA collected information related to alcohol and drug usage while 
experiencing symptoms.  These questions were identified as the questions that would be 
used in the second phase of analysis to control for alcohol and drug abuse in this 
population.  Specifically, on Question O21, participants responded Yes-clean only to be 
included in the response.   
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Alcohol and Drug-Related Questions 
O21 You have told me about things such as reliving the event through dreams, 
memories, or feelings; avoiding things that reminded you of the event; and 
problems with sleep, mood, or thinking.  Did these experiences last longer 
than one month?  Participants responded Yes-clean only were included in the 
response.  
Additionally, participants responded with a “no” on the two questions related to 
alcohol and drug use.   
Clustering at onset. 
A.  Around the time you first had these very intense feelings, were you having 
experiences from 3 or more boxes found on this (ALCOHOL/COCAINE/ 
OPIATES/ OTHER DRUG) sheet?   
Heavy use when not clustering 
B.   Around the time you first had these very intense feelings, were you (drinking 
heavily, using DRUGS) daily or almost daily? 
Data Analysis Plan 
Whole genome typing was done in the original study by Illumina using the 
HumanOmni1_Quad_v1-0_B platform (Gelertner & Krazler, 2010).  The original 
database was exported into the most current version of PLINK (Purcell, 2009), which is a 
free toolset capable of completing analyses on large scale GWAS data.  This toolset is 
appropriate for analyzing phenotype and genotype data.  All four GWAS on PTSD have 
used PLINK software to complete the analysis (Guffanti et al, 2013; Logue et al., 2012; 
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Solovieff et al., 2014; Xie et al., 2013).  Xie et al. (2013) excluded SNPs from study with 
a call rate of < 98%, with minor allele frequencies of < 1%, and controls whose SNPs 
were not in Hardy Weinberg equilibrium (p < 1 x 10
-6
); this was not applied to cases as 
Xie et al. indicated the presence of disease may impact Hardy Weinberg equilibrium 
(Anderson et al., 2010, as cited by Xie et al., 2013).  Logue et al. (2012) excluded SNPs 
if > 5% missing genotypes or if SNPs were rare, defined as < 5% minor allele frequency.   
Guffanti et al. (2013) used SNPs that passed quality control filters that included a call rate 
> 95%, minor allele frequency > 0.01, Hardy Weinberg equilibrium p > 1x10
-6
).  The 
PLINK program has tools within the program to address missingness of data and quality 
control procedures; these tools were used and were consistent with other GWAS 
completed on PTSD.     
Analysis was conducted on the data between cases and controls to identify any 
regions of the genome that reached a genome wide significance threshold.  Thresholds 
that have been established included: p = 5x10
-8
 (Guffanti et al., 2013); p < 10
-5
 for 
evidence of association and p < 5x10
-8
 for genome wide significance (Logue et al., 2012); 
and 6.51 x 10
-8
 for European Americans and 5.75 x 10
-8
 for African Americans (Xie et 
al., 2013).  A genome wide study by Reiner et al. (2011) on white blood cells used p < 
2.5 x 10
-8
.  For the purpose of this study the genome wide association significance was 
established at p = 5x10
-8
 consistent with both Guffanti et al. (2013) and Logue et al. 
(2012).  The PLINK program can be used with Haploview analysis to provide linkage 
disequilibrium statistics, including haplotype blocks, population haplotype frequencies, 
and single marker association statistics, (including r
2
as appropriate).  PLINK software 
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has a program to adjust for population stratification.  These tools were used as 
appropriate.  An odds ratio for genetic alleles between cases and controls was calculated, 
as appropriate to account for effect sizes using chi square with an established statistical 
significance of p < 0.05.  The SPSS software program was also used to study the effect 
size correlation between the independent and dependent variables.  Gene(s) that reached 
the threshold were included in the second phase of analysis for additional testing with the 
main symptoms of PTSD (re-experiencing/intrusion, avoidance/numbing, hyper arousal) 
and the dependent variable of sleep; the second phase of analysis planned for each 
dependent variable to be evaluated independently in the most recent version of SPSS 
using multiple logistical regression to determine if there were any associations.  For 
categorical data from the SSADDA (i.e., yes versus no to the questions) the chi square 
test statistic had an established statistical significance of p < 0.05 (Hebel & McCarter, 
2012).  Covariates evaluated for the second phase of analysis included: age, gender, race, 
stimulant dependence, sedative dependence, tobacco dependence, and alcohol abuse.    
Logistic regression was the statistical tool planned for the second phase of analysis to 
determine if a correlation existed between an identified gene and each of the dependent 
variables.  Other statistical tools planned for the analysis included: the Odds Ratio for any 
significant association identified from the t test and chi square between PTSD cases and 
controls.   
Research Questions and Hypotheses 
The genome wide method is not hypothesis driven but rather discovery driven; 
research questions to be considered are:  
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 Research Question 1: Are there significant genetic alleles associated with 
PTSD? 
 Research Question 2: Is there a significant association between genetic 
allele(s) and the symptoms of PTSD?  
 Research Question 3: Is there a significant association between genetic 
allele(s) and the symptom of sleep? Is either the COMT or RORα, both genes 
that have been identified in sleep and PTSD, associated with sleep?  
Ethical/Privacy Procedures 
In the original study, phs000425.v1.p1, “Alcohol Dependence GWAS in 
European and African Americans” consent was obtained for general research related to 
alcohol and alcohol related phenotypes/disorders (Gelertner & Krazler, 2010).  A data 
access request (DAR) was made to NCBI; I was the Senior/Key Person under the 
direction of Dr. Shen, the Chair of this dissertation study.  A description of the research, 
the purpose of the research study, and a request for identifiable participant data from the 
original GWAS study from the PTSD only variable subset and the control population was 
requested.  I utilized the genomic dataset in accordance with responsible research use and 
handling of genomic databases and database sharing as set forth in the parameters by the 
National Institutes of Health [NIH] (n.d.; NIH, 2007).   
The Code of Conduct for dbGAP approved users was adhered to in this 
dissertation as well as the Policy for Sharing of Data Obtained in NIH Supported or 
Conducted Genome Wide Association Studies (GWAS) (Database of Genotypes and 
Phenotypes, , n.d.).  The Code of Conduct required the researcher to: 
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 Agree to use  and distribute the data only as requested in the Data Access 
Request 
 Refrain from contacting participants from the study without IRB approval 
 Allow only authorized users access to the data, follow relevant security 
procedures, and report any breaches of data 
 Refrain from publishing information prior to the embargo date 
 Acknowledge Intellectual Property Policies of the data 
 Refrain from selling and GWAS information 
 Provide annual progress reports on the GWAS dataset, as appropriate 
           (Database of Genotypes and Phenotypes, n.d.; NIH, n.d.) 
The risk for identification was minimal as normal data that identifies an individual 
(i.e., name, date of birth, etc.) was not included in the dataset (NIH, 2007).  The dataset 
contained a random unique code or identifier not associated with an individual’s 
identifiable data to protect an individual’s privacy and confidentiality (NIH, 2007).  Only 
the original researchers have access to identifiable data (NIH, 2007); I did not have 
access to direct identifiers.  Concerns still existed that individual data could be compared 
with an individual’s genotype; however no additional datasets were used in this study and 
all security procedures were followed (NIH, 2007).  The study was reviewed and 
approved by the Walden University IRB (09-10-14-0027013).     
Security Procedures 
I agreed to follow the data security requirements when using the dataset in 
accordance with the information contained in the Data Use Certificate Agreement and 
89 
 
 
completed all required trainings from the NIH Information and Security and Privacy 
Training Awareness (Database of Genotypes and Phenotypes, 2010).  The Data Use 
Certificate indicated the dataset can be used in conjunction with substance abuse studies.  
As mentioned only a subsection of the dataset was requested (Database of Genotypes and 
Phenotypes, 2010).   
The Database of Genotypes and Phenotypes (2013) security procedures for 
accessing de-identified individual (personal) level data were followed to ensure access to 
the data were limited only to individuals involved in this dissertation.  The data were 
downloaded to a secure computer and saved on an external hard drive that was encrypted 
and password protected (Database of Genotypes and Phenotypes, 2013).   The password 
was a secure password and was at least 8 characters in length and contained the 
following: lower case, upper case, numerals and special characters (Database of 
Genotypes and Phenotypes, 2013).  Physical safety was considered with the data that 
included minimizing access to the data outside of the immediate research area and 
keeping all data in a locked location (Database of Genotypes and Phenotypes, 2013).  The 
data were accessed in conjunction with the PLINK software that was also downloaded to 
the hard drive.  Analysis of data occurred with programs on the external hard drive.  Now 
that the dissertation is completed all data has been deleted with the exception of the 
minimum data required to comply with the appropriate data retention policies of the 
university (Database of Genotypes and Phenotypes, 2013).        
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Implications 
This research provided information about genetic factors associated with PTSD.    
Positive Social Change implications included bringing attention to the genetic risk factors 
for PTSD to the research community; Genome wide research on PTSD has not had as 
much focus as other disorders such as major depression or schizophrenia (Cornelius et 
al., 2010).  With many veterans returning to the United States following the recent war  
prevention and the importance of effective PTSD diagnosis and treatment is at the 
forefront of public health.  Studying the whole genome identified additional correlations 
previously undiscovered, which could generate new research areas or topics for future 
research (Cornelius et al., 2010).  Additionally, this research added to the existing GWAS 
on PTSD and contributed to building the framework for future studies that focus on 
PTSD.    
Summary 
A GWA study, using a case control study was used to examine the genomes of 
cases with PTSD and controls.  Any gene that reached genome wide significance went on 
to phase two of analysis.  Chapter 4 provides the results of this study.     
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Chapter 4: Results 
Introduction 
This purpose of this dissertation was to examine the genome of individuals with 
PTSD and the genome of non-PTSD controls to discover whether there were any allele(s) 
that reach genome-wide significance.  Genetic allele(s) reaching genome-wide 
significance were moved to a second phase of analysis with the symptoms of PTSD, 
specifically the symptom of sleep.  A genome-wide association study method is not 
hypothesis driven but rather discovery driven; therefore, specific hypotheses were not 
proposed.  The following research questions guided the research: 
 Research Question 1: Are there significant genetic alleles associated with 
PTSD? 
 Research Question 2: Is there a significant association between genetic 
allele(s) and the symptoms of PTSD? 
 Research Question 3: Is there a significant association between genetic 
allele(s) and the symptom of sleep? Is either the COMT or RORα, both genes 
that have been identified in sleep and PTSD, associated with sleep? 
Chapter 4 begins with a review of the process for obtaining the database for the analysis, 
followed by a review of the study population, including descriptive and univariate 
statistics.  The next section contains a review of covariates to be included in the second 
analysis should an allele reach genome-wide significance.  Results from the genome-wide 
association are presented along with responses to the research questions.  The chapter 
concludes with a summary of the results and a transition to Chapter 5.  
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Data Collection 
A data access request (DAR) was initially made to and then approved by [Request 
#32920-2] the National Center for Biotechnology Information Genotypes and Phenotypes 
(NCBI dbGAP) at the National Institutes of Health for research on alcohol and alcohol-
related phenotypes/disorders.  The Walden University Office of Research and Sponsored 
Programs coordinated the application process; I was identified as the senior/key person 
under the direction of Dr. Shen, Chair.  The consent for this research was granted for 
general research use with respect to alcohol and alcohol-related phenotype disorders.  
Access of Alcohol Dependence GWAS in European and African-Americans was 
approved as Project #7620, “A Genome Wide Association Study on the Sleep Symptom 
of Post Traumatic Stress Disorder.”  Walden IRB approval was obtained conditionally 
before requesting the database and received final approval (09-10-14-0027013) following 
NCBI approval. 
The original study, phs000425.v1.p1, “Alcohol Dependence GWAS in European 
and African Americans,” was transferred from dbGAP using the Aspera Connect 3.5.2 
secure transfer protocols and downloaded to an external encrypted hard drive (Gelertner 
& Krazler, 2010).  Files were decrypted using the SRA Toolkit (NCBI, 2015) and the 
repository key provided by NCBI, then extracted twice prior to being ready for use.  All 
analyses were conducted on a Windows 8 operating system. 
The original study focused on alcohol dependence, cocaine, and opioid genetics 
and collected 3,258 genomic samples from individuals over three projects at Yale and 
Rutgers University and Coriell Institute for Medical Research (Gelernter, 2010; Gelertner 
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& Krazler, 2010).  Quality control measures were implemented that included removing 
samples with poor performance (30), gender discrepancies (53), unexpected genotyping 
duplicates (141), and low volume (33).  Data cleaning removed another 114 samples, and 
43 samples had some other anomaly or discrepancy (Gelernter, 2010).  Some samples 
may have accounted for more than one quality concern (Gelernter, 2010).  Gelernter 
(2010) indicated that “the best indicator for sample data quality for Illumina Infinium 
chemistry and Genome Studio calling algorithm is the call rate” (p. 1).  Following quality 
control measures, 2,932 samples were identified as high quality (90% call rate).   
There were some discrepancies identified from the plan presented in Chapter 3.  
The original information on the dbGAP website indicated that information was available 
on 500 PTSD cases and 491controls.  When the database was received, the files of 2,909 
individuals were reviewed.  The affection status of the participants was not coded in the 
genotyping files.  An additional phenotype file included with the study identified the 24 
variables noted on the website, including the PTSD phenotype; however, there were no 
identifiers for control subjects only.  Therefore, after consultation with Dr. Shen, the 
study proceeded with the genomic data from 435 PTSD cases and 2,445 non-PTSD 
controls.  There were 29 participants with unknown phenotype information included in 
the demographic characteristics section but were removed from the genomic portion of 
the study.  Covariates provided in the phenotype files included age, gender, race, sedative 
dependence, stimulant dependence, tobacco dependence, and responses to seven 
questions on alcohol dependence from the SSADDA.  Demographic characteristics are 
provided in Table 5.
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Table 5 
Descriptive Characteristics of Cases and Controls 
  
PTSD cases 
 
Non-PTSD 
controls 
 
Unknown 
 
Group comparison 
 N (%) / Mean 
(SD) 
N (%) /  
Mean (SD) 
N (%) / Mean 
(SD) 
 
p value* 
Number of 
participants 
435 2,445 29 
 
 
 
Age  
 
40.6  
(9.2) 
 
40.1  
(10.2) 
 
42.5  
(8.5) 
 
 
0.27781 
Gender    .00 / λ.007 
     Males 190 (43.7%) 1,421  
(58.1%) 
13  
(44.83%) 
 
      
     Females 
 
245 (56.3%) 
 
1,024  
(41.9%) 
 
16  
(55.17) 
 
Race     
0.011 / λ1.0^ 
     Native 
American 
 1  
(.04%) 
 
  
     Asian   
 
  
     Pacific 
Islander 
  
 
  
 
     African 
American  
 
258  
(59.3 %) 
 
1,651  
(67.5%) 
 
18  
(62.1%) 
 
 
     Caucasian  177  
(40.7%) 
792  
(32.4%) 
10  
(34.5%) 
 
 
     Other  1  
(0.4%) 
1 
(3.4%) 
 
*p-value from continuous variables using unpaired t test (p < .05); ^Monte Carlo estimate 
for Pearson chi square used and λ for categorical variables.   
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The PTSD prevalence rate in the sample population of the study was 15%, which 
is considerably higher than the prevalence rate of PTSD in the general population, 3.6% 
(National Comorbidity Survey, 2007).  Alonso et al. (2004) found that the prevalence rate 
for PTSD in Europeans over the past 12 months was 0.9% (95% CI 0.7-1.1).  African 
Americans had lifetime prevalence rates of 8.7% compared to Whites, whose rate was 
7.0-7.4% (Roberts et al., 2011).  The prevalence rate for this study was more consistent 
with the long-term PTSD prevalence rate noted by Boscarino et al. (2013), which was 
14.3% (95% CI – 11.1-11.8).  External validity is limited only to the population under 
study. 
Univariate analyses using SPSS Statistics Student Version 21 examined age, 
gender, and race between PTSD cases and non-PTSD controls.  Age was evaluated using 
the unpaired t test for continuous variables (p < .05).  Age was not significant (p = 
0.27781). Monte Carole estimate for Pearson chi square and lambda (λ) was used for 
nominal categorical variables of gender and race.  Gender was significant using chi 
square, but lambda indicated no relationship (p = .00; λ .007).  Monte Carlo was 
significant for race, and lambda indicated a relationship (p = 0.011; λ 1.0); race was 
identified as a covariate for the second analysis.   
Confounding variables identified in the literature included BMI, age, gender, 
race/ethnicity, use of anxiolytics, antidepressants, socioeconomic status, type and 
intensity of trauma, education, rural/urban, co-occurring disorders such as major 
depressive disorder, drug dependence, substance abuse, Axis 2 disorders, and age of 
traumatic exposure (Babson et al., 2011; Frans et al., 2005; Krakow, Germain, et al., 
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2001; Krakow, Hollifield, et al., 2001).  Initially, it was thought that the database would 
only include age, gender, race, and substance abuse as potential covariates.  However, 
additional covariates included in the phenotype data included sedative dependence, 
stimulant dependence, and tobacco dependence.  Only tobacco dependence was 
significant (p = .000 and λ 1.0) among the possible additional covariates and was also 
identified as a covariate for the second analysis.  Table 6 provides details on sedative 
dependence, stimulant dependence, and tobacco dependence.   
Table 6 
Covariates: Sedative, Stimulant, and Tobacco Dependence 
 PTSD cases Non-PTSD 
controls 
Unknown Group comparison 
 
 N / (%)  N / (%)  N / (%)  p value* 
 
Number of participants 435 2,445 29  
 
Sedative dependence Abuse – 14 
(3%) 
 
Unaffected – 
398 (92%) 
 
Dependence 
– 23 (5%) 
Abuse – 60 
(2.5%) 
 
Unaffected – 
2,324 (95%) 
 
Dependence – 61 
(2.5%) 
Abuse – 6 
(21%) 
 
Unaffected – 
23 (79%) 
 
Dependence – 
3 (10%) 
.000 / λ could not be 
computed 
 
Stimulant dependence Abuse – 6 
(1%) 
 
Unaffected – 
399 (92%) 
 
Dependence 
– 30 (7%) 
Abuse – 49 (2%) 
 
 
Unaffected – 
2,326 (95%) 
 
Dependence – 70 
(3%) 
Abuse – 6 
(21%) 
 
Unaffected – 
19 (65%) 
 
Dependence – 
4 (14%) 
.000 / λ could not be 
computed 
 
Tobacco dependence Abuse – 0  
 
Unaffected – 
92 (21%) 
 
Dependence 
– 343 (79%) 
Abuse – 1 
 
Unaffected – 
1,068 (44%) 
 
Dependence – 
1,376 (56%) 
Abuse – 1 
(4%) 
Unaffected – 
0 
 
Dependence – 
28 (96%) 
.000 / λ 1.0 
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Seven questions on alcohol dependence from the SSADDA were also included in 
the phenotype files; 2 x 2 tables were created for these questions.  Refer to Table 7.  
Lambda was only calculated on Question 6 – alcohol withdrawal symptoms and showed 
a weak association.    Lambda could not be calculated on any of the other alcohol 
questions from the SSADDA because the asymptomatic standard error was zero.  
Alcohol Dependence was not identified as a covariate for the second analysis.      
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Table 7 
Alcohol Dependence 
Alcohol dependence item    
Q1 - Excessive time related to substance PTSD cases (n 
= 435) 
Non-PTSD controls (n 
= 2,445) 
Group comparison - 
.000 / λ  
could not be computed 
Unaffected 136 (31%) 1,175 (48%)  
Affected 299 (69%) 1,270 (52%)  
Q2 - Unsuccessful attempts to cut down 
on use 
   
.000 / λ could not be 
computed 
Unaffected 54 (12%) 677 (28%) 
 
 
Affected 381 (88%) 1,768 (72%)  
Q3 - Tolerance    .000 / λ could not be 
computed 
Unaffected 93 (21%) 881 (36%) 
 
 
Affected 342 (79%) 1,564 (64%)  
Q4 - Impaired social or work activities 
due to substance 
 
  .000 / λ could not be 
computed 
Unaffected 79 (18%) 914 (37%) 
 
 
Affected 356 (82%) 1,531 (63%)  
Q5 - Use more than intended 
 
  .000 / λ could not be 
computed 
Unaffected 17 (4%) 512 (21%) 
 
 
Affected 418 (96%) 1933 (79%)  
Q6 - Alcohol withdrawal symptoms   .000 / .020 
Unaffected  
194 (45%) 
 
1,563 (64%) 
 
 
Affected 241 (55%) 882 (36%)  
Q7 - Use despite physical or 
psychological consequences 
  .000 / λ could not be 
computed  
Unaffected 102 (23%) 1,217 (50%)  
Affected 333 (77%) 1,228 (50%)  
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Results 
Plink Analysis 
The NCBI database came with PLINK ready files in the form of bed 
(bed/bim/fam) files and ped files.  Since bed files were already provided by NCBI 
additional bed files were not required to be made using PLINK.  The subject level PLINK 
ready files were used for quality control measures and the association study.  The family 
file had the affection status for all individuals in the study (n = 2,909) set to missing 
therefore filtering only controls in the dataset was not possible.  A request for an updated 
file of the non-PTSD individuals identifying “pure controls” (meaning individuals 
without PTSD or alcohol dependence) for the study was requested but not provided by 
dbGAP.  An alternate phenotype file identifying the affection status of PTSD (n = 435) 
and non-PTSD controls (n = 2,445) was provided by dbGAP.   
The genomic data were analyzed using PLINK software v1.07 (Purcell, 2009; 
Purcell et al., 2007).  The analysis identified 1,140,419 markers to be included from 
2,909 individuals.  There were 435 cases, 2,445 controls and 29 with missing phenotypes.  
A total of 2,880 founders were included in the analysis.  PLINK set to missing 5,577 
heterozygous haplotype genotypes.  After Hardy Weinberg equilibrium (HWE p < = 
0.001) 216,526 markers were excluded (61,608 from cases and 216,526 from controls).  
The genotyping rate was 88.52%.  There were 129,182 SNPs that failed missingness tests 
(geno > 0.1) and 292,691 SNPs that failed frequency testing (minor allele frequency, 
MAF < 0.01).  The 29 cases with a missing phenotype status were pruned from the 
analysis.  After frequency and genotyping pruning, 632,686 SNPs were included in the 
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association analysis with 435 PTSD cases, 2,445 non-PTSD controls that included 1,611 
males and 1,269 females.  The output file in PLINK generates a row for each SNP 
association result.  The fields include the chromosome (CHR), the SNP identifier, the 
location of the SNP which is known as the physical distance (bp), allele 1 (or the minor 
allele), the frequency of the minor allele in cases (F_A) and the frequency of the minor 
allele in controls (F-U), allele 2 (or the major allele), the chi-square statistic (1 df), the p 
value for this test, and the effect size or odds ratio (OR).   
In response to Research Question 1: Are there significant genetic alleles 
associated with PTSD? The genome wide association threshold that was established for 
the purpose of this dissertation and to identify these alleles was p = 5x10
-8
 (Guffanti et 
al., 2013).  After quality controls measures mentioned above, there were signals from two 
SNPs that exceeded the established genome wide threshold: SNP rs13160949 on 
chromosome 5 (p = 7.33x10
-9
, OR: 1.565) and SNP rs2283877 on chromosome 22 (p = 
2.55x10
-8
, OR: 1.748).  Results from the case/control association generated a large 
volume of association results.  The top ten SNPs are provided in Table 8.   
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Table 8 
Genome-Wide Association Results 
CHR SNP BP A1 F_A F_U A2 CHIS
Q 
P* OR 
5 rs13160949 107060238 G 0.3575 0.2623 A 33.45 7.33x10
-9
* 1.565 
 
22 rs2283877 29838195 A 0.1725 0.1065 G 31.02 2.55x10
-8
* 1.748 
 
11 rs12788610 382953 A 0.1767 0.112 G 28.78 8.12x10
-8
         1.701 
 
23 rs6641588 3565302 G 0.4183 0.315 A 27.32 1.72x10
-7
         1.564 
 
2 rs17327578 59851548 A 0.1046 0.0574
6 
G 27.16 1.87x10
-7
 1.916 
11 rs2280134 3638095 A 0.3655 0.4609 G 27.16 1.87x10
-7
 0.673 
 
20 rs6075106 16689497 G 0.177 0.1141 A 26.98 2.06x10
-7
 1.67 
 
15 rs776689 40132542 G 0.3828 0.4775 A 26.67 2.42x10
-7
        0.678 
 
11 rs7479832 393939 A 0.149 0.0922
2 
G 26.07 3.29x10
-7
        1.723 
 
11 Rs7941314 1.24x10
-8
         G 0.3425 0.2592 A 25.91 3.58x10
-7
        1.489 
*Genome-wide threshold: p = 5x10-8     
 
There were concerns the initial significant results for the two SNPS were due to 
population stratification; therefore the same quality measures were repeated using the 
tools in PLINK to adjust for population stratification (Purcell et al., 2007).  Dadd, Weale, 
and Lewis (2009) indicate population stratification is a concern for genome wide studies.  
PLINK uses Genomic Control, Bonferroni, Holm, Sidak, and False Discovery Rate 
(FDR) to adjust for multiple testing, population stratification, and false positives.  
According to Clark, Anderson, Pettersson, Cardon, Morris, and Zondervan (2011) both 
the Bonferroni and Sidak (Single Step – SS; Step Down - SD) can be used for 
adjustments related to associations identified at the SNP level; the Sidak however, “in 
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GWA studies comprising dense sets of markers, is unlikely to be true and both 
corrections are conservative” (p. 123).  The Holm can be used in place of Bonferroni but 
is considered the weaker of the two tests (Clark et al., 2011).  The FDR is used to identify 
false discovery of association results (Clark et al., 2011).  Two methods of the FDR are 
provided by PLINK based on the individuals who developed the tests, BH for Benjamini 
and Hochberg (1995) and BY for Benjamini and Yekutieli (2001).  Genomic Control is 
considered a reasonable correction method used to control for population stratification 
(Dadd et al., 2009).  For the purpose of this dissertation, Genomic Control was used to 
correct for population stratification.  PLINK identified the genomic inflation factor 
(based on median chi-squared) as 1.46541; the mean chi-squared statistic was 1.41316.  
The top ten results from multiple test corrected significance values for 632,686 tests are 
provided in Table 9.    
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Table 9 
Corrected Significance Values 
CHR SNP Unadjusted GC BONF / 
HOLM* 
SIDAK 
SS/SD 
FRD_BH FDR_BY 
5 rs13160949 7.33x10-9* 
 
1.78x10-6 0.004638 0.004627 0.004638 0.06463 
22 rs2283877 2.55x10-8* 
 
4.20x10-6 0.01614 0.01601 0.008071 0.1125 
11 rs12788610 8.12x10-8  
       
9.36x10-6 0.05136 0.05006 0.01712 0.2386 
23 rs6641588 1.72x10-7 
         
1.58x10-5 0.109 0.1033 0.01862 0.2595 
2 rs1732758 1.87x10-7 
 
1.67x10-5 0.1185 0.1117 0.01862 0.2595 
11 rs2280134 1.87x10-7 
 
1.67x10-5 0.1185 0.1118 0.01862 0.2595 
20 rs6075106 2.06x10-7 
 
1.78x10-5 0.1304 0.1222 0.01862 0.2595 
15 rs776689 2.42x10-7        1.99x10-5 0.153 0.1419 0.01913 0.2666 
11 rs7479832 3.29x10-7 
 
2.46x10-5 0.2078 0.1877 0.02246 0.3129 
11 rs7941314 3.58x10-7 2.62x10-5 0.2267 0.2029 0.02246 0.3129 
*Bonferroni and HOLM rates and SIDAK rates (SS and SD) were identical and combined in Table 9, 
 
Neither SNP rs13160949 nor SNP rs2283877 maintained their genome wide 
significance following corrected tests for multiple testing, population stratification, and 
false discovery.  The corrected value significance value using genomic control for SNP 
rs13160949 was 1.78x10
-6
 and for SNP rs2283877 was 4.20x10
-6
.   
Following this initial analysis any allele that exceeded the genome wide 
association threshold would move on to the second phase of the analysis, which consisted 
of the remaining two research questions:   
 
 Research Question 2: Is there a significant association between genetic 
allele(s) and the symptoms of PTSD? 
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 Research Question 3: Is there a significant association between genetic 
allele(s) and the symptom of sleep? Is either the COMT or RORα, both genes 
that have been identified in sleep and PTSD, associated with sleep? 
There were no allele’s that maintained genome wide significance following correction for 
multiple testing therefore there was no second analysis.   
Summary 
Results from the genome wide association method examining PTSD cases and 
non-PTSD controls identified two genetic alleles that reached genome wide significance 
in initial testing but neither survived corrected significance values.  In response to 
Research Q1: there were no significant genetic alleles associated with PTSD.  In response 
to research Q2 and Q3 there were no genetic alleles that moved to the second phase of 
analysis related to the symptoms associated with PTSD, specifically the symptom of 
sleep.   
 Chapter 4 reviewed some of the concerns associated with genome wide 
association studies, including concerns related to multiple testing, population 
stratification, and false discovery of positive associations (Type I error).  Chapter 5 will 
review the results and identify additional concerns including Type II error.  Limitations to 
the study, recommendations for future research, and social change implications will 
conclude Chapter 5.    
  
105 
 
 
Chapter 5: Results and Discussion 
Introduction 
This purpose of this dissertation was to examine the genome of individuals with 
PTSD and that of non-PTSD controls to discover if there were any allele(s) that reached 
genome-wide significance.  Any genetic allele(s) reaching genome-wide significance 
would move to a second phase of analysis to determine whether there was an association 
between the genetic allele(s) and the symptoms of PTSD, specifically the symptom of 
sleep.  The genome-wide association threshold that was established for the purpose of 
this dissertation was p = 5x10
-8
 (Guffanti et al., 2013).  Initial testing done in PLINK 
identified signals from two SNPs that exceeded the established genome-wide threshold: 
SNP rs13160949 on chromosome 5 (p = 7.33x10
-9
, OR: 1.565) and SNP rs2283877 on 
chromosome 22 (p = 2.55x10
-8
, OR: 1.748).  There were concerns that the initial 
significant results might be due to population stratification, multiple testing, or false 
discovery.  Neither SNP maintained its genome-wide significance following tests 
adjusting for multiple testing, population stratification, and false discovery.  The 
corrected significance value using genomic control for SNP rs13160949 was 1.78x10
-6
 
and for SNP rs2283877 was 4.20x10
-6
.  
Following the initial analysis, any allele that exceeded the genome-wide 
association threshold would move on to a second phase of analysis.  There were no 
alleles that maintained genome-wide significance following correction for multiple 
testing; therefore, there was no second analysis.  In response to Research Question 1, 
there were no significant genetic alleles associated with PTSD.  In response to Research 
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Questions 2 and 3, there were no genetic alleles that moved to the second phase of 
analysis related to the symptoms associated with PTSD, specifically the symptom of 
sleep.   
Interpretation of the Findings 
Clark et al. (2011) indicated, “A significant result in an association test rarely 
implies that a SNP is directly influencing disease risk” (p. 125).  The initial finding of 
two SNPS reaching genome-wide significance was thought to be spurious and possibly 
due to population stratification or nonrandom genotyping failure generating false 
positives (Purcell et al., 2007).  Call rates in other GWAS have been 98% (Xie et al., 
2013) and 95% (Guffanti et al., 2013).  The call rate for this study was 88.5%, which is 
lower than other GWAS.  Additionally, in the methodology section of this dissertation, 
Hardy Weinberg equilibrium was set at p > 1x10
-6
; however, using this threshold 
excluded all markers from the study, and therefore the default threshold in PLINK was 
used in the analysis (p < =.001).   The Hardy Weinberg equilibrium test assumes that “in 
a random mating population with no selection, mutation, or migration, allele frequencies 
and genotype frequencies are constant from generation to generation” (Guo & Thompson, 
1992, p. 361).  Additional testing was completed to adjust for multiple testing, population 
stratification, and false discovery.  Neither SNP maintained its genome-wide significance 
threshold following corrected tests.  These tests are designed to address Type I error.  
Although the genome-wide method is not hypothesis driven, these tests were considered 
useful in interpreting the results.     
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The literature reviewed in Chapter 2 on PTSD focused on candidate gene and 
genetic allele studies and GWAS.  Results of the studies indicated associations with 
candidate genes/alleles, mixed results, or no association (Amstadter et al., 2011; Bailey et 
al., 2010; Change et al., 2012; Dragon & Onisczenko, 2009; Guffanti et al., 2013; Hauer 
et al., 2011; Lee et al., 2005; Lee et al., 2006; Lee et al., 2011; Logue et al., 2012; 
Mellman et al., 2009; Morey et al., 2011; Morgan et al., 2003; Pivak et al., 2006; Ressler 
et al., 2011; Sah et al., 2009; Sarapas et al., 2011; Sayin et al., 2010; ;  Segman et al., 
2002; Voisey et al., 2009; Voisey et al., 2010; Xie et al., 2013;).  The results of this study 
are consistent with the finding of no association with PTSD.  Neither of the two SNPs 
(rs13160949 nor SNP rs2283877) has been identified from the peer-reviewed literature in 
Chapter 2.  In fact, there was no information available on either SNP in the dbSNP 
database or via searches in Academic Search Premier, Google Scholar, or PubMed.  
Opensnp indicated SNP rs13160949 (SNP-ID 701967) on chromosome 5 at position 
107696638 has had no mining; no results on PLoS, genome.gov, Personal Genome 
Project, or Mendeley-results (Opensnp, n.d.).  SNP rs2283877 on chromosome 22 was 
listed in ALFRED (The Allele Frequency Database), allele ID SI441126S, position 
31508195 at ribosomal protein S15a pseudogene 37 locus (Kidd, n.d.).  No other 
information was available on either SNP.   
The theoretical/conceptual framework for this study was Walker and van der 
Helm’s (2009) “sleep to remember sleep to forget” framework, which focused on sleep as 
a mechanism for PTSD development.  This framework was chosen based on the 
hypothesis that sleep dysfunction is not just a symptom associated with PTSD but may be 
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a possible pathway for the development of PTSD (Walker & van der Helm, 2009).  There 
were no genetic alleles reaching genome-wide significance that moved onto the second 
phase of analysis; therefore, the results do not lend support for or provide evidence to 
disprove the theoretical/conceptual framework. 
This study found no genetic alleles associated with PTSD, which may be true 
despite limitations noted in the next section.  Questions have been raised related to the 
genome-wide association method, such as the following: Are genotyping technologies 
sophisticated enough to produce robust datasets? Do different SNP arrays affect 
genotypes?  Do using different algorithms affect data?  Do different calling rates impact 
results (Hong et al., 2010)?  Hong et al. (2010) indicated that GWA studies have often 
not been replicated when using similar populations.  The four GWA PTSD studies 
published each identified novel results with minimal replications of the others’ findings 
(Logue et al., 2012; Guffanti et al., 2013; Solovieff et al., 2014;  Xie et al., 2013;).  Du, 
Xie, Chang, Han, and Cao (2012) indicated that GWAS have found associations with 
genetic alleles; however, heritability studies attribute 37-41% of the variance in PTSD to 
genetic factors (Bailey et al., 2010; Goenjian et al., 2012).  Results from this study, if 
they are true, suggest that genetic alleles may not be major contributors to PTSD 
development.  Xie et al. (2013) also suggested that common variants may be minimally 
involved in PTSD risk.  Given the literature, genetic factors likely play a role in PTSD 
risk; however, research efforts may need to be refocused to evaluate genetic factors 
differently.  The most recently published GWAS by Solovieff et al. (2014) did that by 
specifically examining all the candidate genes identified in the literature and conducting 
109 
 
 
separate analyses on the genetic alleles identified in the three previously published 
GWAS (Guffanti et al., 2013; Logue et al., 2012; Xie et al., 2013).  They indicated, 
“PTSD is highly polygenic, influenced by numerous SNPs with weak effects” (Solovieff 
et al., 2014, p. 1872).        
Limitations 
Limitations from Type I errors (falsely reporting an association when there is 
none) in genome-wide association studies include the following: population stratification 
(occurs when cases and controls are not from the same population), multiple testing, false 
discovery, biased selection or misclassification of cases and controls, undocumented or 
cryptic relatedness, and nongenetic confounding variables (Hong et al., 2010; Purcell et 
al., 2007; Zang & Deng, 2010; Zondervan & Cardon, 2007).  Purcell et al. (2007) 
indicated that multiple testing generates “many highly significant results … by chance 
alone, making it hard to distinguish signal from noise” (p. 559).  Another type of error is 
due to nonrandom genotyping (Hong et al., 2010).  This error can occur when a SNP 
genotype is called incorrectly or is not called; if the calling is nonrandom, some 
genotypes (and also phenotypes) may be called more often, leading to a false positive 
association (Purcell et al., 2007).  The initially significant results found in the study may 
have been from any of these concerns.  Initial testing did not adjust for population 
stratification, false discovery, or multiple testing.  The call rate for this study (88%) was 
lower than call rates noted in other GWAS (98% and 95%; Guffanti et al., 2013; Xie et 
al., 2013).  Covariate analyses indicated that both race and tobacco use should be 
included in the second analysis.  The initial study collected genomic data for substance 
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dependence.  When comparing PTSD cases to non-PTSD controls in the covariate 
analysis section in Chapter 4, the majority of questions on alcohol dependence were not 
able to be tested using λ because chi square was .000, suggesting the possibility of 
confounding.  Quality control measures, Hardy Weinberg equilibrium, and corrected 
significance levels using genomic control adjusted for these concerns.  Additional testing 
to address concerns due to undocumented relatedness was not completed given the results 
from adjustments. 
Type II errors (failure to report an association when there is one) can result from 
technical errors in genotyping or genotype measurements (Hong et al., 2010).  Cooley et 
al. (2011) identify a number of problems associated with data accuracy including 
imputation errors when data is entered, differing algorithms being used, genotyping error 
rates due to duplication, and phenotype misclassification.  Errors can also occur at the 
point of diagnosis (sensitivity and specificity; Cooley et al., 2011).  The potential for 
information bias related to misclassification or measurement error (i.e., “biological 
sample collection, processing and storage, sample labeling, DNA extraction and storage, 
laboratory assays, data coding, entry and analysis”) was addressed by ensuring the two 
groups are in Hardy Weinberg equilibrium (HWE) (Garcia-Closas et al., 2004, p. 131).  
However, as previously mentioned, the default HWE (.001) was used in PLINK rather 
than the HWE that was established for the study (p = 1x 10-6) eliminated all SNPs from 
analysis.  Type II errors could also have occurred when the original database did not 
identify the “true controls”, individuals without Alcohol Dependence or PTSD, from the 
original study.  The control population used in the study had 500 individuals without 
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Alcohol Dependence or PTSD and 1,945 with an Alcohol Dependence.  The “true 
controls” were not identified in the database, which likely introduced bias in the results.  
These types of errors would have occurred during the collection of and processing of 
genotype and phenotype information and would not have been addressed by this research 
study, therefore results should be interpreted with caution.   
Another limitation identified with the GWAS method is small to moderate effects 
or Odd Ratio (OR).  Du et al. (2012) indicated that effects from non-genetic risk factors 
typically generated OR’s with two or three fold increases compared to OR’s for genome 
wide studies that only showed modest increases.  Stringer, Wray, Kahn, and Derks (2011) 
stated that GWAS examining single SNPS with dichotomous phenotypes may not 
identify true effect sizes; they indicated that the variance attributed to genetic factors is 
low, particularly in psychiatric disorders.  “One explanation of the missing heritability is 
that complex diseases are caused by a large number of causal variants with small effect 
sizes” (Stringer et al., 2011, p. 1).  Galichon, Mesnard, Hertig, Stengel, and Rondeau 
(2012) indicate that the GWAS method can identify “previously unrecognized sequence 
homologies caused by SNP microarrays that incorrectly associate a phenotype to a given 
locus when in fact the linkage is to another distant locus” (p. 4474).  Galichon et al. 
recommend using quality controls measures but also indicate this could eliminate 
relevant SNPs.  They recommend three additional steps that include the following: 
stratify the data based on sex, check all SNPs identified for “genome wide alignment of 
the SNP-flanking sequences and of the restriction fragments”, and sequence the loci 
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thought to be associated with the SNP to ensure association with the phenotype (Galichon 
et al., 2012, p. 4781).            
Other sources of bias in genetic epidemiology include selection bias, information 
bias, and confounding (Garcia-Closas et al., 2004).  The original study included genomic 
data from participants recruited during three different studies.  It is unknown if the 
distribution of genetic factors were similar between cases and controls.  The potential for 
information bias related to misclassification or measurement error (i.e., “biological 
sample collection, processing and storage, sample labeling, DNA extraction and storage, 
laboratory assays, data coding, entry and analysis”) was addressed by ensuring the two 
groups are in Hardy Weinberg equilibrium (Garcia-Closas et al., 2004, p. 131).  
However, as previously mentioned, the default HWE (.001) was used in PLINK rather 
than the HWE that was established for the study (10-6) which eliminated all SNPs from 
analysis.  Recall bias was minimized as genotypes are stable over time (Botto & Khoury, 
2004).   
The United States Preventative Services Task Force criteria were identified in 
Chapter 1 for evaluating internal validity for individual case control studies (National 
Center for Biotechnology Information, U.S. National Library of Medicine [NCBINLM], 
n.d.).  Internal validity criteria included: valid selection of case, exclusion criteria applied 
equally to cases and controls, an 80% response rate, the same measurements applied to 
cases and controls, and addressing confounding variables (NCBINLM, n.d.).  These 
criteria, with the exception of confounding, were not relevant for this study as the 
requirements were a priori.  Confounding was not a concern as the second phase of 
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analysis in the study did not occur.  Other threats to internal validity such as history, 
maturation, instrumentation, experimental mortality, and selection maturation were not a 
concern (SUU, n.d.).  Testing (i.e. the Hawthorne effect) was identified in Chapter 1 as a 
concern since participants were aware they were participating in a research study.  Recall 
bias is minimized in GWAS and genotypes are stable over time (Botto & Khoury, 2004).   
Results from this study should not be generalized to other populations.  The 
prevalence of PTSD differed in the study population compared to published PTSD 
prevalence rates and the presence of alcohol dependence in the study population may be 
different from individuals with PTSD only.  The lack of a PTSD only population was 
previously identified as a limitation.  The sample size for PTSD cases was small for a 
GWAS study (n = 435) suggesting power may be low.  Other threats to external validity 
such as testing reactivity, interaction effects, reactive effects, and multiple treatment 
interference were not a concern for this study (SUU, n.d.).          
Recommendations 
The GWAS portion of this study was completed however, there were concerns 
identified related to the control population and how this population may have affected the 
results.  The control population which, consisted of all non-PTSD individuals, contained 
a mix of individuals with and without alcohol abuse possibly impacting the identification 
of alleles that would have been appropriate for phase two of the study.  Results of the 
study neither supported nor provided evidence for the theoretical framework, Walker & 
van der Helm’s (2009) ”sleep to remember sleep to forget” framework.  
Recommendations from the literature do support further investigation of PTSD and sleep 
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(Krakow, Germain, et al., 2001; Walker & van der Helm, 2009; Yetkin et al., 2010).  A 
GWA study using PTSD cases and non-PTSD controls, both without the presence of 
alcohol dependence or abuse is recommended.  All GWAS published to date have 
included replication in a different population to substantiate any allele reaching genome-
wide significance; this is recommended for any allele(s) reaching genome wide 
significance (Guffanti et al., 2013; Logue et al., 2012; Solovieff et al., 2014; Xie et al., 
2013).  Appropriate quality control measures (i.e., an adequate call rate, MAF, and 
genotyping) should be implemented.  HWE and adjustments for population stratification, 
multiple testing, and false discovery should be used in any future study.  Additionally, 
follow the recommendations from Galichon et al. (2012) to stratify the data by sex, check 
SNPs flanking sequences and restriction fragments, and sequence the loci thought to be 
associated with the SNP.  Sleep symptoms should be evaluated using a validated 
measurement tool such as the Pittsburg Sleep Quality Index (PSQI) to collect information 
on sleep related concerns (Buysse et al., 1989).  Additionally, the American Psychiatric 
Association’s Diagnostic and Statistical Manual 5 (2013) has been released and has 
updated the criteria used for diagnosing PTSD; future studies should use the updated 
PTSD diagnostic criteria.  Confounding should be minimized by controlling for variables 
identified in the literature: BMI, age, gender, race/ethnicity, use of anxiolytics, 
antidepressants, socioeconomic status, type and intensity of trauma, education, 
rural/urban, co-occurring disorders such as major depressive disorder, drug dependence, 
substance abuse, Axis 2 disorders, and age of traumatic exposure (Babson et al., 2011; 
Frans et al., 2005; Krakow, Germain, et al., 2001; Krakow, Hollifield, et al., 2001).      
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Implications 
Positive Social Change 
PTSD continues to be a public health concern.  The effects of PTSD can be 
experienced years after an event.  Effective treatment is needed for individuals who 
develop this disorder.  This dissertation brought attention to the genetic risk factors 
associated with PTSD to the researcher community; genome wide studies on PTSD have 
not received as much attention as other more prominent mental health conditions such as 
depression or schizophrenia (Cornelius et al., 2010).  When this dissertation was started 
there were no published genome wide association studies on PTSD.  There are now four 
published studies (Guffanti et al., 2013; Logue et al., 2012; Solovieff et al., 2014; Xie et 
al., 2013).  This dissertation contributed to bringing awareness of a possible novel 
pathway for disease development.   The idea of sleep as a possible pathway is in its 
infancy in terms of investigation despite evidence that sleep is intimately involved with 
PTSD.  This dissertation was designed to study PTSD from a broader scope considering 
multiple factors that may be involved with PTSD development.  Initially, by studying the 
entire genome rather than a single candidate gene, then had phase two been able to be 
completed an examination of how genetic risk factors may be associated with symptoms 
and specifically sleep.  Finally, this research provided a framework for other GWA 
studies on PTSD, including limitations with the GWAS method and provided 
recommendations for future research on the potential relationship between sleep and 
PTSD development.    
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Conclusion 
This purpose of this dissertation was to complete a two part analysis with the first 
phase being a genome-wide association study (GWAS) examining the genome of 
individuals with PTSD compared to non-PTSD controls.  Any allele(s) that reached 
genome wide significance would have moved on to the second phase of analysis, 
examining the allele with PTSD symptoms, specifically the symptom of sleep.  Two 
SNPs exceeded the genome wide threshold but did not survive  adjustments for 
population stratification, multiple testing, or false discovery therefore there was no 
second phase of analysis; the results did not lend support for or provide evidence to 
disprove the theoretical/conceptual framework, Walker & van der Helm’s (2009) ”sleep 
to remember sleep to forget”.  Despite limitations associated with the database, this study 
demonstrated the principles of public health and epidemiology.  Specifically by 
collaborating with a large community partner (NCBI) to use existing data resources while 
applying principles of informatics and human genome epidemiology to complete a study 
typically reserved for a large academic or research setting.  This study may open the door 
for other Walden Students to partner with community stakeholders to complete research 
studies using existing data sources.   
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Appendix  
Criterion A: The person has been exposed to a traumatic event in which both of the 
following have been present: 
1) The person has experienced, witnessed, or been confronted with an event 
or events that involve actual or threatened death or serious injury, or a threat to the 
physical integrity of oneself or others. 
2) The person's response involved intense fear, helplessness, or horror. Note: 
in children, it may be expressed instead by disorganized or agitated behavior. 
Criterion B: The traumatic event is persistently re-experienced in at least one (or more) 
of the following ways: 
1) Recurrent and intrusive distressing recollections of the event, including 
images, thoughts, or perceptions. Note: in young children, repetitive play may 
occur in which themes or aspects of the trauma are expressed. 
2) Recurrent distressing dreams of the event. Note: in children, there may be 
frightening dreams without recognizable content 
3) Acting or feeling as if the traumatic event were recurring (includes a sense 
of reliving the experience, illusions, hallucinations, and dissociative flashback 
episodes, including those that occur upon awakening or when intoxicated). Note: 
in children, trauma-specific reenactment may occur. 
4) Intense psychological distress at exposure to internal or external cues that 
symbolize or resemble an aspect of the traumatic event. 
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5) Physiologic reactivity upon exposure to internal or external cues that 
symbolize or resemble an aspect of the traumatic event 
Criterion C: Persistent avoidance of stimuli associated with the trauma and numbing of 
general responsiveness (not present before the trauma), as indicated by at least three (or 
more) of the following: 
1. Efforts to avoid thoughts, feelings, or conversations associated with the 
trauma 
2. Efforts to avoid activities, places, or people that arouse recollections of the 
trauma 
3. Inability to recall an important aspect of the trauma 
4. Markedly diminished interest or participation in significant activities 
5. Feeling of detachment or estrangement from others 
6. Restricted range of affect (e.g., unable to have loving feelings) 
7. Sense of foreshortened future (e.g., does not expect to have a career, 
marriage, children, or a normal life span) 
Criterion D: Persistent symptoms of increasing arousal (not present before the trauma), 
indicated by at least two (or more) of the following: 
1. Difficulty falling or staying asleep 
2. Irritability or outbursts of anger 
3. Difficulty concentrating 
4. Hyper-vigilance 
5. Exaggerated startle response 
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Criterion E: Duration of the disturbance (symptoms in B, C, and D) is more than one 
month. 
Criterion F: The disturbance causes clinically significant distress or impairment in 
social, occupational, or other important areas of functioning. 
Specify if: 
Acute: if duration of symptoms is less than three months 
Chronic: if duration of symptoms is three months or more 
Specify if: 
With Delayed Onset: Onset of symptoms at least six months after the stressor 
Reference 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (Revised 4th ed.). Washington, DC: Author, p. 468. 
 
 
